My NCBISign In
Print View 

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Center for Substance Abuse Treatment. Detoxification and Substance Abuse Treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2006. (Treatment Improvement Protocol (TIP) Series, No. 45.)

Bookshelf ID: NBK64111

Appendix A: Bibliography

  1. Abbott P J. Traditional and Western healing practices for alcoholism in American Indians and Alaska Natives. Substance Use and Misuse. 1998;33(13):2605–2646. [PubMed: 9818991]
  2. Abbott P J, Quinn D, Knox L. Ambulatory medical detoxification for alcohol. American Journal of Drug and Alcohol Abuse. 1995;21(4):549–563. [PubMed: 8561102]
  3. Abbott P J, Weller S B, Delaney H D, Moore B A. Community reinforcement approach in the treatment of opiate addicts. American Journal of Drug and Alcohol Abuse. 1998;24(1):17–30. [PubMed: 9513627]
  4. Adams J B, Wacher A. Specific changes in the glycoprotein components of seromucoid in pregnancy. Clinica Chimica Acta: International Journal of Clinical Chemistry. 1968;21(1):155–157. [PubMed: 5658947]
  5. Addolorato G, Balducci G, Capristo E, Attilia M L, Taggi F, Gasbarrini G, Ceccanti M. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: A randomized comparative study versus benzodiazepine. Alcoholism: Clinical and Experimental Research. 1999a;23(10):1596–1604.
  6. Addolorato G, Capristo E, Gessa G L, Caputo F, Stefanini G F, Gasbarrini G. Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sciences. 1999b;65(14):PL191–PL196. [PubMed: 10530806]
  7. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, Colombo G, Gessa G L, Gasbarrini G. Rapid suppression of alcohol withdrawal syndrome by baclofen. American Journal of Medicine. 2002;112(3):226–229. [PubMed: 11893350]
  8. Administration for Children and Families. SSBG 2002: Helping States Serve the Needs of America's Families, Adults, and Children. Washington, DC: U.S. Department of Health and Human Services, 2002. http://www.acf.hhs.gov/programs/ocs/ssbg/annrpt/2002/index.html[Accessed January 7, 2005].
  9. Ahijevych, K. Nicotine Metabolism Variability and Nicotine Addiction. Bethesda, MD: National Institutes of Health, 1998.
  10. Ahmed S, Chadwick D, Walker R J. The management of alcohol-related seizures: An overview. Hospital Medicine. 2000;61(11):793–796. [PubMed: 11198750]
  11. Alan Guttmacher Institute. Substance Abuse During Pregnancy. State Policies in Brief. New York: Guttmacher Institute, 6-1-2002. http://www.agi-usa.org/pubs/spib_SADP.pdf[Accessed July 19, 2002].
  12. Alen M. Androgenic steroid effects on liver and red cells. British Journal of Sports Medicine. 1985;19(1):15–20. [PMC free article: PMC1478211] [PubMed: 3995222]
  13. Allen K, Dixon M. Psychometric assessment of the Allen Barriers to Treatment Instrument. International Journal of the Addictions. 1994;29(5):545–563. [PubMed: 8034371]
  14. Allhoff T, Renzing-Kohler K, Scherbaum N, Sack S, Kienbaum P. Electrocardiographic abnormalities during recovery from ultra-short opiate detoxification. Addiction Biology. 1999;4(3):337–344. [PubMed: 20575801]
  15. Alling, F.A. Detoxification and treatment of acute sequelae. In: Lowinson, J.H., Ruiz, P., and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins, 1992. pp. 402–415.
  16. Altarriba J, Bauer L M. Counseling the Hispanic client: Cuban Americans, Mexican Americans, and Puerto Ricans. Journal of Counseling and Development. 1998;76(4):389–396.
  17. Alterman A I, Erdlen F R, Murphy E. Alcohol abuse in the psychiatric hospital population. Addictive Behaviors. 1981;6(1):69–73. [PubMed: 7257920]
  18. Altura B M. Introduction to the symposium and overview. Alcoholism: Clinical and Experimental Research. 1986;10:557–559.
  19. Amass L, Ling W, Freese T E, Reiber C, Annon J J, Cohen A J, McCarty D, Reid M S, Brown L S Jr, Clark C, Ziedonis D M, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir J A, Buchan B J, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. American Journal on Addictions. 2004;13(Suppl1):S42–S66. [PMC free article: PMC1255908] [PubMed: 15204675]
  20. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776–789. [PubMed: 11533352]
  21. American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care. 2004;27(Suppl 1):536–546.
  22. American Medical Association. Drug Dependencies as Diseases. Policy Finder. H-95.983. Chicago: American Medical Association, 2002. http://www.ama-assn.org/[Accessed July 9, 2002].
  23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
  24. American Psychiatric Association. Practice guideline for the treatment of patients with nicotine dependence. American Journal of Psychiatry. 1996;153(10):1–31.
  25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000.
  26. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine Dependence, Toxicity, and Abuse. Washington, DC: American Psychiatric Press, 1990.
  27. American Society of Addiction Medicine. Patient Placement Criteria for the Treatment of Substance-Related Disorders: ASAM PPC-2. 2d ed. Revised. Chevy Chase, MD: American Society of Addiction Medicine, 1996.
  28. American Society of Addiction Medicine. Patient Placement Criteria for the Treatment of Substance-Related Disorders: ASAM PPC-2R. 2d-Revised ed. Chevy Chase, MD: American Society of Addiction Medicine, 2001.
  29. Anderson C B, Wetter D W. Behavioral and pharmacologic approaches to smoking cessation. Cancer and Metastasis Reviews. 1997;16(3–4):393–404. [PubMed: 9433647]
  30. Anderson D J. Delivery of essential services to alcoholics through the “continuum of care” Cancer Research. 1979;39(7 pt 2):2855–2858. [PubMed: 221109]
  31. Anderson D W, Bowland B J, Cartwright W S, Bassin G. Service-level costing of drug abuse treatment. Journal of Substance Abuse Treatment. 1998;15(3):201–211. [PubMed: 9633032]
  32. Anderson F, Kiefer F. Depressive mood and craving during alcohol withdrawal: Association and interaction. German Journal of Psychiatry. 2004;7(2):6–11.
  33. Anderson F, Paluzzi P, Lee J, Huggins G, Huggins G. Illicit use of clonidine in opiate-abusing pregnant women. Obstetrics and Gynecology. 1997a;90(5):790–794. [PubMed: 9351766]
  34. Anderson M, Elk R, Anderes R L. Social, ethical and practical aspects of perinatal substance use. Journal of Substance Abuse Treatment. 1997b;14(5):481–486. [PubMed: 9437618]
  35. Andrulis D, Hopkins S. Public hospitals and substance abuse services for pregnant women and mothers: Implications for managed-care programs and Medicaid. Journal of Urban Health. 2001;78(1):181–198. [PubMed: 11368197]
  36. Angres, D.H., and Easton, M. Treatment management for acute and continuing care. In: Smith, D.E., and Easton, M., eds. Manual of Therapeutics for Addictions. New York: Wiley-Liss, 1997. pp. 269–284.
  37. Anton R F. What is craving?: Models and implications for treatment. Alcohol Research and Health. 1999;23(3):165–173. [PubMed: 10890811]
  38. Anton R F. Carbohydrate-deficient transferrin for detection and monitoring of sustained heavy drinking. What have we learned? Where do we go from here? Alcohol. 2001;25(3):185–188. [PubMed: 11839464]
  39. Anton R F, Kranzler H R, McEvoy J P, Moak D H, Bianca R. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology. 1997;131:123–129. [PubMed: 9201799]
  40. Apte M V, Wilson J S, Korsten M A. Alcohol-related pancreatic damage: Mechanisms and treatment. Alcohol Health and Research World. 1997;21(1):13–20. [PubMed: 15706759]
  41. Aragon, T., and Sande, M.A. Infective endocarditis. In: Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby, 1994. pp. 189–202.
  42. Arfken C L, Klein C, di Menza S, Schuster C R. Gender differences in problem severity at assessment and treatment retention. Journal of Substance Abuse Treatment. 2001;20(1):53–57. [PubMed: 11239728]
  43. Argyropoulos S V, Nutt D J. The use of benzodiazepines in anxiety and other disorders. European Neuropsychopharmacology. 1999;9(Suppl 6):S407–S412. [PubMed: 10622687]
  44. Armenian S H, Chutuape M A, Stitzer M L. Predictors of discharges against medical advice from a short-term hospital detoxification unit. Drug and Alcohol Dependence. 1999;56(1):1–8. [PubMed: 10462086]
  45. Ashton, C.H. Benzodiazepine abuse. The Ashton Manual, 2002. http://www.benzo.org.uk/ashbzab.htm[Accessed January 21, 2005].
  46. Asociacion Mixta Progresista v. H.E.W. Civil Number C72882 (N.D. Cal. 1976), 1976.
  47. Aszalos R, McDuff D R, Weintraub E, Montoya I, Schwartz R. Engaging hospitalized heroin-dependent patients into substance abuse treatment. Journal of Substance Abuse Treatment. 1999;17(1–2):149–158. [PubMed: 10435263]
  48. Atkinson R M. Alcohol problems of the elderly. Alcohol and Alcoholism. 1987;22(4):415–417. [PubMed: 3322312]
  49. Atkinson R M. Aging and alcohol use disorders: Diagnostic issues in the elderly. International Psychogeriatrics. 1990;2(1):55–72. [PubMed: 2101298]
  50. Atkinson, R.M., Ganzini, L., and Bernstein, M.J. Alcohol and substance use disorders in the elderly. In: Birren, J.E., Sloane, R.B., and Cohen, G.D., eds. Handbook of Mental Health and Aging. 2d ed. San Diego, CA: Academic Press, 1992. pp. 515–555.
  51. Atkinson R M, Ryan S C, Turner J A. Variation among aging alcoholic patients in treatment. American Journal of Geriatric Psychiatry. 2001;9(3):275–282. [PubMed: 11481136]
  52. Avants S K, Margolin A, Holford T R, Kosten T R. A randomized controlled trial of auricular acupuncture for cocaine dependence. Archives of Internal Medicine. 2000;160(15):2305–2312. [PubMed: 10927727]
  53. Avants S K, Margolin A, Kosten T R, Rounsaville B J, Schottenfeld R S. When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. Journal of Consulting and Clinical Psychology. 1998;66(6):924–931. [PubMed: 9874905]
  54. Aviram R B, Rhum M, Levin F R. Psychotherapy of adults with comorbid attention deficit hyperactivity disorder and psychoactive substance use disorder. Journal of Psychotherapy Practice and Research. 2001;10(3):179–186. [PMC free article: PMC3330647] [PubMed: 11402081]
  55. Ballenger J C, Post R M. Kindling as a model for alcohol withdrawal syndromes. British Journal of Psychiatry. 1978;133(1):1–14. [PubMed: 352467]
  56. Balster, R.L. The pharmacology of inhalants. In: Graham, A.W., Schultz, T.K., Mayo-Smith, M.F., Ries, R.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003. pp. 295–304.
  57. Banys P, Clark H W, Tusel D J, Sees K, Stewart P, Mongan L, Delucchi K, Callaway E. An open trial of low dose buprenorphine in treating methadone withdrawal. Journal of Substance Abuse Treatment. 1994;11(1):9–15. [PubMed: 8201637]
  58. Barclay D M. Tuberculosis in the homeless. Archives of Family Medicine. 1995;4(6):541–546. [PubMed: 7773431]
  59. Bates J H, Stead W W. The history of tuberculosis as a global epidemic. Medical Clinics of North America. 1993;77(6):1205–1217. [PubMed: 8231408]
  60. Beck, A.J., Karberg, J.C., and Harrison, P.M. Prison and Jail Inmates at Midyear 2001. NCJ 191702. Washington, DC: Bureau of Justice Statistics, 2002. http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim01.pdf[Accessed April 25, 2002].
  61. Becker A B, Strain E C, Bigelow G E, Stitzer M L, Johnson R E. Gradual dose taper following chronic buprenorphine. American Journal on Addictions. 2001;10(2):111–121. [PubMed: 11444154]
  62. Becker, K.L., and Walton-Moss, B. Detecting and addressing alcohol abuse in women. Nurse Practitioner 26(10):13–16, 19–23; quiz 24–25, 2001.
  63. Beckley-Barrett L M, Mutch P B. Position of the American Dietetic Association: Nutrition intervention in treatment and recovery from chemical dependency. Journal of the American Dietetic Association. 1990;90(9):1274–1277. [PubMed: 2168909]
  64. Bell K, Cramer-Benjamin D, Anastas J. Predicting length of stay of substance-using pregnant and postpartum women in day treatment. Journal of Substance Abuse Treatment. 1997;14(4):393–400. [PubMed: 9368217]
  65. Bennefield, R.L. Health Insurance Coverage: 1997. Current Population Reports. Washington, DC: Bureau of the Census, 1998. http://www.census.gov/prod/3/98pubs/p60–202.pdf[Accessed June 4, 2002].
  66. Benowitz, N.L. The use of biologic fluid samples in assessing tobacco smoke consumption. In: Gravowksi, J., and Bell, C.S., eds. Measurement in the Analysis and Treatment of Smoking Behavior. NIDA Research Monograph Series, Number 48. Rockville, MD: National Institute on Drug Abuse, 1983. pp. 6–26.
  67. Benowitz N L, Gourlay S G. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy. Journal of the American College of Cardiology. 1997;29(7):1422–1431. [PubMed: 9180099]
  68. Benowitz N L, Perez-Stable E J, Herrera B, Jacob P III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. Journal of the National Cancer Institute. 2002;94(2):108–115. [PubMed: 11792749]
  69. Benowitz N L, Zevin S, Jacob P III. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. British Journal of Clinical Pharmacology. 1997;43(3):259–267. [PMC free article: PMC2042749] [PubMed: 9088580]
  70. Beresford, T.P. Alcohol and aging: Looking ahead. In: Beresford, T.P., and Gomberg, E., eds. Alcohol and Aging. New York: Oxford University Press, 1995. pp. 327–336.
  71. Bernadt M W, Murray R M. Psychiatric disorder, drinking and alcoholism: What are the links? British Journal of Psychiatry. 1986;148:393–400. [PubMed: 3730705]
  72. Bernat J L. Informed consent. Muscle and Nerve. 2001;24(5):614–621. [PubMed: 11317270]
  73. Beuger M, Tommasello A, Schwartz R, Clinton M. Clonidine use and abuse among methadone program applicants and patients. Journal of Substance Abuse Treatment. 1998;15(6):589–593. [PubMed: 9845872]
  74. Bickel W K, Stitzer M L, Bigelow G E, Liebson I A, Jasinski D R, Johnson R E. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics. 1988;43(1):72–78. [PubMed: 3275523]
  75. Blachly, P., Casey, D., Marcel, L., and Denney, D. Rapid detoxification from heroin and methadone using naloxone. A model for the syndrome. In: Senay, E., Shortz, V., and Alkesne, H., eds. Development in the Field of Drug Abuse. Cambridge, MA: Schenkman, 1975. pp. 327–336.
  76. Blankfield A. Psychiatric symptoms in alcohol dependence: Diagnostic and treatment implications. Journal of Substance Abuse Treatment. 1986;3(4):275–278. [PubMed: 3586078]
  77. Blechner B, Butera A. Health Insurance Portability and Accountability Act of 1996 (HIPAA): A provider's overview of new privacy regulations. Connecticut Medicine. 2002;66(2):91–95. [PubMed: 11908191]
  78. Blondal T, Gudmundsson L J, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up. British Medical Journal. 1999;318:285–288. [PMC free article: PMC27708] [PubMed: 9924052]
  79. Bobo J K, Davis C M. Cigarette smoking cessation and alcohol treatment. Addiction. 1993;88(3):405–412. [PubMed: 8384911]
  80. Booth B M, Blow F C. The kindling hypothesis: Further evidence from a U.S. national study of alcoholic men. Alcohol and Alcoholism. 1993;28(5):593–598. [PubMed: 8274184]
  81. Booth B M, Russell D W, Soucek S, Laughlin P R. Social support and outcome of alcoholism treatment: An exploratory analysis. American Journal of Drug and Alcohol Abuse. 1992;18(1):87–101. [PubMed: 1562009]
  82. Borgdorff M W, Behr M A, Nagelkerke N J, Hopewell P C, Small P M. Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. International Journal of Tuberculosis and Lung Disease. 2000;4(4):287–294. [PubMed: 10777075]
  83. Boucher, T.A., Kiesuk, T.J., and Trachtenberg, A.I. Complementary and alternative therapies. In: Graham, A.W., Schultz, T.K., Mayo-Smith, M.F., Ries, R.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003. pp. 509–532.
  84. Bowles T M, Sommi R W, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy. 2001;21(2):254–257. [PubMed: 11213862]
  85. Bradley K A, Boyd-Wickizer J, Powell S H, Burman M L. Alcohol screening questionnaires in women: A critical review. Journal of the American Medical Association. 1998;280(2):166–171. [PubMed: 9669791]
  86. Brady K T, Grice D E, Dustan L, Randall C. Gender differences in substance use disorders. American Journal of Psychiatry. 1993;150(11):1707–1711. [PubMed: 8214180]
  87. Brady K T, Randall C L. Gender differences in substance use disorders. Psychiatric Clinics of North America. 1999;22(2):241–252. [PubMed: 10385931]
  88. Brauer R B, Liebermann-Meffert D, Stein H J, Bartels H, Siewert J R. Boerhaave's syndrome: Analysis of the literature and report of 18 new cases. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus. 1997;10(1):64–68.
  89. Brems C. Cultural issues in psychological assessment: Problems and possible solutions. Journal of Psychological Practice. 1998;4(2):88–117.
  90. Brewer C. Ultra-rapid, antagonist-precipitated opiate detoxification under general anesthesia or sedation. Addiction Biology. 1997;2(3):291–302.
  91. Brouette T, Anton R. Clinical review of inhalants. American Journal on Addictions. 2001;10(1):79–94. [PubMed: 11268830]
  92. Brower K J, Mudd S, Blow F C, Young J P, Hill E M. Severity and treatment of alcohol withdrawal in elderly versus younger patients. Alcoholism: Clinical and Experimental Research. 1994;18(1):196–201.
  93. Brown M E, Anton R F, Malcolm R, Ballenger J C. Alcohol detoxification and withdrawal seizures: Clinical support for a kindling hypothesis. Biological Psychiatry. 1988;23:507–514. [PubMed: 3345323]
  94. Brown P J, Recupero P R, Stout R. PTSD substance abuse comorbidity and treatment utilization. Addictive Behaviors. 1995;20(2):251–254. [PubMed: 7484319]
  95. Brown S A, Schuckit M A. Changes in depression among abstinent alcoholics. Journal of Studies on Alcohol. 1988;49(5):412–417. [PubMed: 3216643]
  96. Brumbaugh A G. Acupuncture: New perspectives in chemical dependency treatment. Journal of Substance Abuse Treatment. 1993;10(1):35–43. [PubMed: 8450571]
  97. Buchert R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, Jenicke L, Bohuslavizki K H, Clausen M. Long-term effects of “ecstasy” abuse on the human brain studied by FDG PET. Nuclear Medicine Communications. 2001;22(8):889–897. [PubMed: 11473208]
  98. Bucholz, K.K., Sheline, Y., and Helzer, J.E. The epidemiology of alcohol use, problems, and dependence in elders: A review. In: Beresford, T.P., and Gomberg, E., eds. Alcohol and Aging. New York: Oxford University Press, 1995. pp. 19–41.
  99. Budney A J, Hughes J R, Moore B A, Novy P L. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Archives of General Psychiatry. 2001;58(10):917–924. [PubMed: 11576029]
  100. Bureau of Justice Assistance. Byrne Formula Grant Program Guidance and Application Kit. Washington, DC: Bureau of Justice Assistance, 2002. http://www.ojp.usdoj.gov/BJA/html/ByrneFormula.htm[Accessed May 21, 2002].
  101. Burke A P, Kalra P, Li L, Smialek J, Virmani R. Infectious endocarditis and sudden unexpected death: Incidence and morphology of lesions in intravenous addicts and non-drug abusers. Journal of Heart Valve Disease. 1997;6(2):198–202. [PubMed: 9130133]
  102. Burkett G, Gomez-Marin O, Yasin S Y, Martinez M. Prenatal care in cocaine-exposed pregnancies. Obstetrics and Gynecology. 1998;92(2):193–200. [PubMed: 9699750]
  103. Burling T A, Burling A S, Latini D. A controlled smoking cessation trial for substance-dependent inpatients. Journal of Consulting and Clinical Psychology. 2001;69(2):295–304. [PubMed: 11393606]
  104. Burling T A, Marshall G D, Seidner A L. Smoking cessation for substance abuse inpatients. Journal of Substance Abuse. 1991;3(3):269–276. [PubMed: 1668228]
  105. Burnam M A, Hough R L, Karno M, Escobar J I, Telles C A. Acculturation and lifetime prevalence of psychiatric disorders among Mexican Americans in Los Angeles. Journal of Health and Social Behavior. 1987;28(1):89–102. [PubMed: 3571910]
  106. Butcher, J.N., Nezami, E., and Exner, J. Psychological assessment of people in diverse cultures. In: Kazarian, S.S., and Evans, D.R., eds. Cultural Clinical Psychology: Theory, Research, and Practice. New York: Oxford University Press, 1998. pp. 61–105.
  107. Buttner A, Mall G, Penning R, Weis S. The neuropathology of heroin abuse. Forensic Science International. 2000;113(1–3):435–442. [PubMed: 10978659]
  108. Buxton N, McConachie N S. Amphetamine abuse and intracranial haemorrhage. Journal of the Royal Society of Medicine. 2000;93(9):472–477. [PMC free article: PMC1298104] [PubMed: 11089483]
  109. Caetano R, Clark C L, Tam T. Alcohol consumption among racial/ethnic minorities: Theory and research. Alcohol Health and Research World. 1998;22(4):233–238. [PubMed: 15706749]
  110. Callahan K P, Malinin A I, Atar D, Serebruany V L. Platelet activation as a universal trigger in the pathogenesis of acute coronary events after cocaine abuse. Swiss Medicine Weekly. 2001;131(33–34):487–489.
  111. Canino G J, Bird H R, Shrout P E, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guzman A, Guevara L M, Costas H. The Spanish Diagnostic Interview Schedule. Reliability and concordance with clinical diagnoses in Puerto Rico. Archives of General Psychiatry. 1987;44(8):720–726. [PubMed: 3498455]
  112. Caraveo-Anduaga J, Colmenares B, Eduardo S, Gabriela J. Psychiatric morbidity in Mexico City: Prevalence and comorbidity during a lifetime. Salud Mental. 1999;22:62–67.
  113. Carey K B, Purnine D M, Maisto S A, Carey M P, Barnes K L. Decisional balance regarding substance use among persons with schizophrenia. Community Mental Health Journal. 1999;35(4):289–299. [PMC free article: PMC2430516] [PubMed: 10452697]
  114. Carise, D., and McLellan, A.T. Increasing Cultural Sensitivity of the Addiction Severity Index (ASI): An Example With Native Americans in North Dakota. Special Report. Rockville, MD: Center for Substance Abuse Treatment, 1999.
  115. Carroll, K.M., ed. Improving Compliance With Alcoholism Treatment. Project MATCH Monograph Series Vol. 6. NIH Publication No. 97-4143. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 1997.
  116. Carter N, Rutty G N, Milroy C M, Forrest A R. Deaths associated with MBDB misuse. International Journal of Legal Medicine. 2000;113(3):168–170. [PubMed: 10876990]
  117. Castro, F.G., and Tafoya-Barraza, H.M. Treatment issues with Latinos addicted to cocaine and heroin. In: Garcia, J.G., and Zea, M.C., eds. Psychological Interventions and Research With Latino Populations. Boston: Allyn and Bacon, 1997. pp. 191–216.
  118. Center for Substance Abuse Prevention. Communication Strategy Guide: A Look at Methamphetamine Use Among Three Populations. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000. http://media.shs.net/prevline/pdfs/index.pdf[Accessed March 11, 2004].
  119. Center for Substance Abuse Treatment. Improving Treatment for Drug-Exposed Infants. Treatment Improvement Protocol (TIP) Series 5. DHHS Publication No. (SMA) 95-3057. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993a.
  120. Center for Substance Abuse Treatment. Pregnant, Substance-Using Women. Treatment Improvement Protocol (TIP) Series 2. DHHS Publication No. (SMA) 93-1998. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993b.
  121. Center for Substance Abuse Treatment. Screening for Infectious Diseases Among Substance Abusers. Treatment Improvement Protocol (TIP) Series 6. DHHS Publication No. (SMA) 95-3060. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993c.
  122. Center for Substance Abuse Treatment. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. DHHS Publication No. (SMA) 93-1991. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993d.
  123. Center for Substance Abuse Treatment. Assessment and Treatment of Cocaine-Abusing Methadone-Maintained Patients. Treatment Improvement Protocol (TIP) Series 10. DHHS Publication No. (SMA) 94-3003. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994a.
  124. Center for Substance Abuse Treatment. Assessment and Treatment of Patients with Coexisting Mental Illness and Alcohol and Other Drug Abuse. Treatment Improvement Protocol (TIP) Series 9. DHHS Publication No. (SMA) 94-2078. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994b.
  125. Center for Substance Abuse Treatment. Combining Substance Abuse Treatment With Intermediate Sanctions for Adults in the Criminal Justice System. Treatment Improvement Protocol (TIP) Series 12. DHHS Publication No. (SMA) 94-3004. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994c.
  126. Center for Substance Abuse Treatment. Intensive Outpatient Treatment for Alcohol and Other Drug Abuse. Treatment Improvement Protocol (TIP) Series 8. DHHS Publication No. (SMA) 99-3306. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994d.
  127. Center for Substance Abuse Treatment. Screening and Assessment for Alcohol and Other Drug Abuse Among Adults in the Criminal Justice System. Treatment Improvement Protocol (TIP) Series 7. DHHS Publication No. (SMA) 94-2076. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994e.
  128. Center for Substance Abuse Treatment. Simple Screening Instruments for Outreach for Alcohol and Other Drug Abuse and Infectious Diseases. Treatment Improvement Protocol (TIP) Series 11. DHHS Publication No. (SMA) 94-2094. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1994f.
  129. Center for Substance Abuse Treatment. Alcohol and Other Drug Screening of Hospitalized Trauma Patients. Treatment Improvement Protocol (TIP) Series 16. DHHS Publication No. (SMA) 95-3041. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995a.
  130. Center for Substance Abuse Treatment. Combining Alcohol and Other Drug Treatment with Diversion for Juveniles in the Justice System. Treatment Improvement Protocol (TIP) Series 21. DHHS Publication No. (SMA) 95-3051. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995b.
  131. Center for Substance Abuse Treatment. Developing State Outcomes Monitoring Systems for Alcohol and Other Drug Abuse Treatment. Treatment Improvement Protocol (TIP) Series 14. DHHS Publication No. (SMA) 95-3031. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995c.
  132. Center for Substance Abuse Treatment. Detoxification From Alcohol and Other Drugs. Treatment Improvement Protocol (TIP) Series 19. DHHS Publication No. (SMA) 95-3046. Rockville, MD: Center for Substance Abuse Treatment, 1995d.
  133. Center for Substance Abuse Treatment. LAAM in the Treatment of Opiate Addiction. Treatment Improvement Protocol (TIP) Series 22. DHHS Publication No. (SMA) 95-3052. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995e.
  134. Center for Substance Abuse Treatment. Matching Treatment to Patient Needs in Opioid Substitution Therapy. Treatment Improvement Protocol (TIP) Series 20. DHHS Publication No. (SMA) 95-3049. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995f.
  135. Center for Substance Abuse Treatment. Planning for Alcohol and Other Drug Abuse Treatment for Adults in the Criminal Justice System. Treatment Improvement Protocol (TIP) Series 17. DHHS Publication No. (SMA) 95-3039. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995g.
  136. Center for Substance Abuse Treatment. The Role and Current Status of Patient Placement Criteria in the Treatment of Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 13. DHHS Publication No. (SMA) 95-3021. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995h.
  137. Center for Substance Abuse Treatment. The Tuberculosis Epidemic: Legal and Ethical Issues for Alcohol and Other Drug Abuse Treatment Providers. Treatment Improvement Protocol (TIP) Series 18. DHHS Publication No. (SMA) 95-3047. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1995i.
  138. Center for Substance Abuse Treatment. Treatment Drug Courts: Integrating Substance Abuse Treatment With Legal Case Processing. Treatment Improvement Protocol (TIP) Series 23. DHHS Publication No. (SMA) 96-3113. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1996.
  139. Center for Substance Abuse Treatment. A Guide to Substance Abuse Services for Primary Care Clinicians. Treatment Improvement Protocol (TIP) Series 24. DHHS Publication No. (SMA) 97-3139. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1997a.
  140. Center for Substance Abuse Treatment. Substance Abuse Treatment and Domestic Violence. Treatment Improvement Protocol (TIP) Series 25. DHHS Publication No. (SMA) 97-3163. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1997b.
  141. Center for Substance Abuse Treatment. Comprehensive Case Management for Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series 27. DHHS Publication No. (SMA) 98-3222. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998a.
  142. Center for Substance Abuse Treatment. Continuity of Offender Treatment for Substance Use Disorders From Institution to Community. Treatment Improvement Protocol (TIP) Series 30. DHHS Publication No. (SMA) 98-3245. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998b.
  143. Center for Substance Abuse Treatment. Contracting for Managed Substance Abuse and Mental Health Services: A Guide for Public Purchasers. Technical Assistance Publication (TAP) Series 22. DHHS Publication No. (SMA) 98-3173. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998c.
  144. Center for Substance Abuse Treatment. Measuring the Cost of Substance Abuse Treatment Services: An Overview. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998d.
  145. Center for Substance Abuse Treatment. Naltrexone and Alcoholism Treatment. Treatment Improvement Protocol (TIP) Series 28. DHHS Publication No. (SMA) 98-3206. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998e.
  146. Center for Substance Abuse Treatment. Substance Abuse Among Older Adults. Treatment Improvement Protocol (TIP) Series 26. DHHS Publication No. (SMA) 98-3179. Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment, 1998f.
  147. Center for Substance Abuse Treatment. Substance Use Disorder Treatment for People With Physical and Cognitive Disabilities. Treatment Improvement Protocol (TIP) Series 29. DHHS Publication No. (SMA) 98-3249. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998g.
  148. Center for Substance Abuse Treatment. Brief Interventions and Brief Therapies for Substance Abuse. Treatment Improvement Protocol (TIP) Series 34. DHHS Publication No. (SMA) 99-3353. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999a.
  149. Center for Substance Abuse Treatment. Cultural Issues in Substance Abuse Treatment. DHHS Publication No. (SMA) 99-3278. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999b.
  150. Center for Substance Abuse Treatment. Enhancing Motivation for Change in Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series 35. DHHS Publication No. (SMA) 99-3354. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999c.
  151. Center for Substance Abuse Treatment. Screening and Assessing Adolescents for Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 31. DHHS Publication No. (SMA) 99-3282. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999d.
  152. Center for Substance Abuse Treatment. Treatment for Stimulant Use Disorders. Treatment Improvement Protocol (TIP) Series 33. DHHS Publication No. (SMA) 99-3296. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999e.
  153. Center for Substance Abuse Treatment. Treatment of Adolescents With Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 32. DHHS Publication No. (SMA) 99-3283. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1999f.
  154. Center for Substance Abuse Treatment. Changing The Conversation: Improving Substance Abuse Treatment. The National Treatment Improvement Plan Initiative: Panel Reports, Public Hearings, and Participant Acknowledgements. DHHS Publication No. (SMA) 00-3479. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000a.
  155. Center for Substance Abuse Treatment. Changing The Conversation: Improving Substance Abuse Treatment. The National Treatment Improvement Plan Initiative. DHHS Publication No. (SMA) 00-3480. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000b.
  156. Center for Substance Abuse Treatment. Integrating Substance Abuse Treatment and Vocational Services. Treatment Improvement Protocol (TIP) Series 38. DHHS Publication No. (SMA) 00-3470. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000c.
  157. Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons With Child Abuse and Neglect Issues. Treatment Improvement Protocol (TIP) Series 36. DHHS Publication No. (SMA) 00-3357. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000d.
  158. Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons With HIV/AIDS. Treatment Improvement Protocol (TIP) Series 37. DHHS Publication No. (SMA) 00-3459. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000e.
  159. Center for Substance Abuse Treatment. A Provider's Introduction to Substance Abuse Treatment for Lesbian, Gay, Bisexual, and Transgender Individuals. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2001.
  160. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004a.
  161. Center for Substance Abuse Treatment. Substance Abuse Treatment and Family Therapy. Treatment Improvement Protocol (TIP) Series 39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004b.
  162. Center for Substance Abuse Treatment. Substance Abuse Treatment: Group Therapy. Treatment Improvement Protocol (TIP) Series 41. DHHS Publication No. (SMA) 05-3991. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005a.
  163. Center for Substance Abuse Treatment. Substance Abuse Treatment for Adults in the Criminal Justice System. Treatment Improvement Protocol (TIP) Series 44. DHHS Publication No. (SMA) 05-4056. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005b.
  164. Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series 42. DHHS Publication No. (SMA) 05-3992. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005c.
  165. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005d.
  166. Center for Substance Abuse Treatment. Improving Cultural Competence in Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development a.
  167. Center for Substance Abuse Treatment. Substance Abuse: Administrative Issues in Outpatient Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development c.
  168. Center for Substance Abuse Treatment. Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development d.
  169. Center for Substance Abuse Treatment. Substance Abuse Treatment: Addressing the Specific Needs of Women. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development e.
  170. Center for Substance Abuse Treatment. Substance Abuse Treatment: Men's Issues. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development g.
  171. Center for Substance Abuse Treatment. Substance Abuse and Trauma. Treatment Improvement Protocol (TIP) Series. Rockville, MD: Substance Abuse and Mental Health Services Administration, in development h.
  172. Centers for Disease Control and Prevention. HIV Prevention Community Planning for HIV Prevention Cooperative Agreement Recipients. Atlanta, GA: Centers for Disease Control and Prevention, 1999. http://www.cdc.gov/hiv/pubs/hiv-cp.pdf[Accessed July 3, 2003].
  173. Centers for Disease Control and Prevention. HIV Prevention Strategic Plan Through 2005. Atlanta, GA: Centers for Disease Control and Prevention, 2001. http://www.cdc.gov/nchstp/od/news/prevention.pdf[Accessed July 3, 2003].
  174. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2000. Morbidity and Mortality Weekly Report 51(29):642–645, 2002a. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5129a3.htm[Accessed January 14, 2005].
  175. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2001 13(2):1–44, 2002b. http://www.cdc.gov/hiv/stats/hasr1302.pdf[Accessed July 3, 2003].
  176. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2004. Morbidity and Mortality Weekly Report. 54(44):1121–1124, 2005. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5444a2.htm[Accessed March 8, 2006].
  177. Centers for Disease Control and Prevention and Office of Minority Health. Native Hawaiian & Other Pacific Islander (NHOPI) Populations. 2004. http://www.cdc.gov/omh/Populations/NHOPI/NHOPI.htm[Accessed February 12, 2004].
  178. Centers for Medicare and Medicaid Services. Your Medicare Coverage. Baltimore: U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, 2002. http://www.medicare.gov/Coverage/Home.asp[Accessed November 7, 2002].
  179. Chakko S, Myerburg R J. Cardiac complications of cocaine abuse. Clinical Cardiology. 1995;18(2):67–72. [PubMed: 7720292]
  180. Chambers H F, Morris D L, Tauber M G, Modin G. Cocaine use and the risk for endocarditis in intravenous drug users. Annals of Internal Medicine. 1987;106(6):833–836. [PubMed: 3579070]
  181. Chan A W K, Pristach E A, Welte J W, Russell M. Use of the TWEAK test in screening for alcoholism/heavy drinking in three populations. Alcoholism, Clinical and Experimental Research. 1993;17(6):1188–1192.
  182. Chance J F. Emergency department treatment of alcohol withdrawal seizures with phenytoin. Annals of Emergency Medicine. 1991;20(5):520–522. [PubMed: 2024792]
  183. Chang, P. Treating Asian/Pacific American addicts and their families. In: Krestan, J.A., ed. Bridges to Recovery: Addiction, Family Therapy, and Multicultural Treatment. New York: Free Press, 2000. pp. 192–218.
  184. Chappel J N, DuPont R L. Twelve-step and mutual help programs for addictive disorders. Psychiatric Clinics of North America. 1999;22(2):425–446. [PubMed: 10385942]
  185. Charney D S, Heninger G R, Kleber H D. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. American Journal of Psychiatry. 1986;143(7):831–837. [PubMed: 3717421]
  186. Charney D S, Riordan C E, Kleber H D, Murburg M, Braverman P, Sternberg D E, Heninger G R, Redmond D E. Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Archives of General Psychiatry. 1982;39(11):1327–1332. [PubMed: 7138234]
  187. Chavkin W, Breitbart V, Elman D, Wise P H. National survey of the states: Policies and practices regarding drug-using pregnant women. American Journal of Public Health. 1998;88(1):117–119. [PMC free article: PMC1508376] [PubMed: 9584016]
  188. Chen Y R, Swann A C, Johnson B A. Stability of diagnosis in bipolar disorder. Journal of Nervous & Mental Disease. 1998;186(1):17–23. [PubMed: 9457143]
  189. Cherpitel C J. Screening for alcohol problems in the emergency room: A rapid alcohol problems screen. Drug and Alcohol Dependence. 1995;40(2):133–137. [PubMed: 8745135]
  190. Cherpitel C J. Comparison of screening instruments for alcohol problems between Black and White emergency room patients from two regions of the country. Alcoholism: Clinical and Experimental Research. 1997;21(8):1391–1397.
  191. Childress A R, Mozley P D, McElgin W, Fitzgerald J, Reivich M, O'Brien C P. Limbic activation during cue-induced cocaine craving. American Journal of Psychiatry. 1999;156(1):11–18. [PMC free article: PMC2820826] [PubMed: 9892292]
  192. Chiles J A, Von Cleve E, Jemelka R P, Trupin E W. Substance abuse and psychiatric disorders in prison inmates. Hospital Community Psychiatry. 1990;41(10):1132–1134. [PubMed: 2242882]
  193. Christophersen, A.S. Amphetamine designer drugs: An overview and epidemiology. Toxicology Letters (Mar 15):112,113–127,131, 2000.
  194. Church O M, Anderson R. Managed care in the substance abuse arena: Challenges and choices. Part II. Journal of Substance Use. 2000;4(3):103–105.
  195. Chutuape M A, Jasinski D R, Fingerhood M I, Stitzer M L. One-, three-, and six-month outcomes after brief inpatient opioid detoxification. American Journal of Drug and Alcohol Abuse. 2001;27(1):19–44. [PubMed: 11373035]
  196. Ciraulo D A, Alderson L M, Chapron D J, Jaffe J H, Subbarao B, Kramer P A. Imipramine disposition in alcoholics. Journal of Clinical Psychopharmacology. 1982;2(1):2–7. [PubMed: 7068940]
  197. Ciraulo D A, Jaffe J H. Tricyclic antidepressants in the treatment of depression associated with alcoholism. Journal of Clinical Psychopharmacology. 1981;1(3):146–150. [PubMed: 7298891]
  198. Clark, H.W., McClanahan, T.M., and Sees, K.L. Substance abuse services in systems of care: Linkages and issues in serving culturally diverse populations. In: Hernandez, M., and Isaacs, M.R., eds. Promoting Cultural Competence in Children's Mental Health Services. Baltimore: Paul H. Brookes Publishing, 1998. pp. 207–227.
  199. Closser M H, Blow F C. Special populations: Women, ethnic minorities, and the elderly. Psychiatric Clinics of North America. 1993;16(1):199–209. [PubMed: 8456045]
  200. Cochran S D, Mays V M. Relation between psychiatric syndromes and behaviorally defined sexual orientation in a sample of the US population. American Journal of Epidemiology. 2000;151(5):516–523. [PubMed: 10707921]
  201. Coffey, R.M., Mark, T., King, E., Harwood, H., McKusick, D., Genuardi, J., Dilonardo, J., and Chalk, M. National Estimates of Expenditures for Substance Abuse Treatment, 1997. DHHS Publication No. SMA 01-3511. Rockville, MD: Center for Substance Abuse Treatment, 2001. http://www.samhsa.gov/centers/csat/content/idbse/sa01.pdf[Accessed August 4, 2003].
  202. Coffey S F, Dansky B S, Carrigan M H, Brady K T. Acute and protracted cocaine abstinence in an outpatient population: A prospective study of mood, sleep and withdrawal symptoms. Drug and Alcohol Dependence. 2000;59:277–286. [PubMed: 10812287]
  203. Collins, K.S., Hughes, D.L., Doty, M.M., Ives, B.L., Edwards, J.N., and Tenney, K. Diverse Communities, Common Concerns: Assessing Health Care Quality For Minority Americans. The Commonwealth Fund, 2002. http://www.kaisernetwork.org/health_cast/uploaded_files/collins_diversecommunities_523.pdf[Accessed January 14, 2005].
  204. Comer V G, Annitto W J. Buprenorphine: A safe method for detoxifying pregnant heroin addicts and their unborn. American Journal on Addictions. 2004;13(3):317–318. [PubMed: 15370952]
  205. Comfort, M., Hagan, T., and Kaltenbach, K. Psychosocial History. Philadelphia: Family Center, Thomas Jefferson University, 1996.
  206. Comfort M, Zanis D A, Whiteley M J, Kelly-Tyler A, Kaltenbach K A. Assessing the needs of substance abusing women: Psychometric data on the psychosocial history. Journal of Substance Abuse Treatment. 1999;17(1–2):79–83. [PubMed: 10435254]
  207. Compton W M III, Cottler L B, Ben-Abdallah A, Phelps D L, Spitznagel E L, Horton J C. Substance dependence and other psychiatric disorders among drug dependent subjects: Race and gender correlates. American Journal on Addictions. 2000;9(2):113–125. [PubMed: 10934573]
  208. Connors G J, Carroll K M, DiClemente C C, Longabaugh R, Donovan D M. The therapeutic alliance and its relationship to alcoholism treatment participation and outcome. Journal of Consulting and Clinical Psychology. 1997;65(4):588–598. [PubMed: 9256560]
  209. Connors G J, DiClemente C C, Dermen K H, Kadden R, Carroll K M, Frone M R. Predicting the therapeutic alliance in alcoholism treatment. Journal of Studies on Alcohol. 2000;61(1):139–149. [PubMed: 10627108]
  210. Conyne R K. What to look for in groups: Helping trainees become more sensitive to multicultural issues. Journal for Specialists in Group Work. 1998;23(1):22–32.
  211. Cook C A, Booth B M, Blow F C, Gogineni A, Bunn J Y. Alcoholism treatment, severity of alcohol-related medical complications, and health services utilization. Journal of Mental Health Administration. 1992;19(1):31–40. [PubMed: 10128721]
  212. Cook J W, Spring B, McChargue D E, Borrelli B, Hitsman B, Niaura R, Keuthen N J, Kristeller J. Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. Psychopharmacology. 2004;173:153–159. [PMC free article: PMC1847574] [PubMed: 14727000]
  213. Cooper-Patrick L, Gallo J J, Powe N R, Steinwachs D S, Eaton W W, Ford D E. Mental health service utilization by African Americans and Whites: The Baltimore Epidemiologic Catchment Area Follow-Up. Medical Care. 1999;37(10):1034–1045. [PubMed: 10524370]
  214. Corcoran, K., and Vandiver, V. Maneuvering the Maze of Managed Care: Skills for Mental Health Practitioners. New York: The Free Press, 1996.
  215. Costa L G, Guizzetti M, Burry M, Oberdoerster J. Developmental neurotoxicity: Do similar phenotypes indicate a common mode of action? A comparison of fetal alcohol syndrome, toluene embryopathy and maternal phenylketonuria. Toxicology Letters. 2002;127(1–3):197–205. [PubMed: 12052659]
  216. Cote G, Hodgins S. Co-occurring mental disorders among criminal offenders. Bulletin of the American Academy of Psychiatry and the Law. 1990;18(3):271–281. [PubMed: 2245243]
  217. Cottler L B, Shillingtron A M, Compton W M I, Mager D, Spitznagel E L. Subjective reports of withdrawal among cocaine users: Recommendations for DSM-IV. Drug and Alcohol Dependence. 1993;33:97–104. [PubMed: 8261885]
  218. Covey L S, Glassman A H, Stetner F, Becker J. Effect of history of alcoholism or major depression on smoking cessation. American Journal of Psychiatry. 1993;150(10):1546–1547. [PubMed: 8379564]
  219. Covey L S, Sullivan M A, Johnston J A, Glassman A H, Robinson M D, Adams D P. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs. 2000;59(1):17–31. [PubMed: 10718098]
  220. Cox G B, Walker R D, Freng S A, Short B A, Meijer L, Gilchrist L. Outcome of a controlled trial of the effectiveness of intensive case management for chronic public inebriates. Journal of Studies on Alcohol. 1998;59(5):523–532. [PubMed: 9718104]
  221. Coyhis, D. Culturally specific addiction recovery for Native Americans. In: Krestan, J., ed. Bridges To Recovery: Addiction, Family Therapy, and Multicultural Treatment. New York: The Free Press, 2000. pp. 77–114.
  222. Craig T J, DiBuono M. Recognition of comorbid psychopathology by staff of a drug detoxification unit. The American Journal on Addictions. 1996;5(1):76–80.
  223. Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L S, Muenz L R, Thase M E, Weiss R D, Gastfriend D R, Woody G E, Barber J P, Butler S F, Daley D, Salloum I, Bishop S, Najavits L M, Lis J, Mercer D, Griffin M L, Moras K, Beck A T. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Archives of General Psychiatry. 1999;56(6):493–502. [PubMed: 10359461]
  224. Crystal M. Ferguson, et al., Petitioners v. City of Charleston et al. No. 99-936 Supreme Court of the United States, 1999.
  225. Cunradi C B, Caetano R, Schafer J. Alcohol-related problems, drug use, and male intimate partner violence severity among U.S. couples. Alcoholism: Clinical and Experimental Research. 2002;26(4):493–500.
  226. Curley, B. Arcane Laws Hinder ER Interventions for Alcohol, Other Drugs. Join Together Online. 2002. http://www.jointogether.org/sa/news/features/reader/0%2C1854%2C554030%2C00.html[Accessed October 17, 2002].
  227. Curran H V, Monaghan L. In and out of the K-hole: A comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction. 2001;96(5):749–760. [PubMed: 11331033]
  228. Dackis C A. A commentary on “The role of laboratory tests for alcoholism treatment” Journal of Substance Abuse Treatment. 2001;20(1):87–88. [PubMed: 11239732]
  229. Dackis, C.A., and Gold, M.S. Inpatient treatment of drug and alcohol addiction. In: Miller, N.S., ed. Comprehensive Handbook of Drug and Alcohol Addiction. New York: Marcel Dekker, Inc., 1991. pp. 1233–1244.
  230. Dackis, C.A., Gold, M.S., and Estroff, T.W. Inpatient treatment of addiction. In: Treatments of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association. Arlington, VA: American Psychiatric Association, 1989. pp. 1359–1379.
  231. Dackis C A, O'Brien C P. Cocaine dependence: A disease of the brain's reward centers. Journal of Substance Abuse Treatment. 2001;21:111–117. [PubMed: 11728784]
  232. Dackis C A, O'Brien C P. Cocaine dependence: The challenge for pharmacotherapy. Current Opinion in Psychiatry. 2002;15:261–267.
  233. Dale L C, Hurt R D, Offord K P, Lawson G M, Croghan I T, Schroeder D R. High-dose nicotine patch therapy: Percentage of replacement and smoking cessation. Journal of the American Medical Association. 1995;274(17):1353–1358. [PubMed: 7563559]
  234. Daley M, Argeriou M, McCarty D. Substance abuse treatment for pregnant women: A window of opportunity? Addictive Behaviors. 1998;23(2):239–249. [PubMed: 9573427]
  235. Daley M, Argeriou M, McCarty D, Callahan J, Shepard D, Williams C. The impact of substance abuse treatment modality on birth weight and health care expenditures. Journal of Psychoactive Drugs. 2001;33(1):57–66. [PubMed: 11333002]
  236. Dansky B S, Saladin M E, Brady K T, Kilpatrick D G, Resnick H S. Prevalence of victimization and posttraumatic stress disorder among women with substance use disorders: Comparison of telephone and in-person assessment samples. International Journal of the Addictions. 1995;30(9):1079–1099. [PubMed: 7591350]
  237. D'Archangelo, E. Substance abuse in later life. Canadian Family Physician 39:1986-1988, 1991-1993, 1993.
  238. Dart R C, Kuffner E K, Rumack B H. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: A systematic review. American Journal of Therapeutics. 2000;7(2):123–134. [PubMed: 11319580]
  239. D'Aunno, T. Linking of substance-abuse treatment and primary health care. In: Egertson, J.A., Fox, D.M., and Leshner, A.I., eds. Treating Drug Abusers Effectively. Malden, MA: Blackwell Publishers, 1997. pp. 311–331.
  240. D'Avanzo C E. Southeast Asians: Asian-Pacific Americans at risk for substance misuse. Substance Use and Misuse. 1997;32(7–8):829–848. [PubMed: 9220559]
  241. Dean M, Stock B, Patterson R J, Levy G. Serum protein binding of drugs during and after pregnancy in humans. Clinical Pharmacology and Therapeutics. 1980;28(2):253–261. [PubMed: 7398192]
  242. Dell'Italia, L. Chest pain. In: Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby, 1994. pp. 86–92.
  243. Dempsey D A, Benowitz N L. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Safety. 2001;24(4):277–322. [PubMed: 11330657]
  244. Denning P. Strategies for implementation of harm reduction in treatment settings. Journal of Psychoactive Drugs. 2001;33(1):23–26. [PubMed: 11332997]
  245. Dennison S J. Clonidine abuse among opiate addicts. Psychiatric Quarterly. 2001;72(2):191–195. [PubMed: 11433883]
  246. Department of Veterans Affairs. CHAMPVA Handbook. Denver, CO: Department of Veterans Affairs, Health Administration Center, 2001. http://www.va.gov/hac/champva/handbook/chandbook.htm[Accessed May 21, 2002].
  247. Deutsch J A, Walton N Y. Diazepam maintenance of alcohol preference during alcohol withdrawal. Science. 1977;198(4314):307–309. [PubMed: 561997]
  248. Diamant K, Fischer G, Schneider C, Lenzinger E, Pezawas L, Schindler S, Eder H. Outpatient opiate detoxification treatment with buprenorphine: Preliminary investigation. European Addiction Research. 1998;4(4):198–202. [PubMed: 9852372]
  249. Dickinson, W.E., Mayo-Smith, M.F., and Eickelberg, S.J. Management of sedative-hypnotic intoxication and withdrawal. In: Graham, A.W., Schultz, T.K., Mayo-Smith, M.F., Ries, R.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003. pp. 633–649.
  250. DiClemente C C. Motivation for change: Implications for substance abuse treatment. Psychological Science. 1999;10(3):209–213.
  251. DiClemente, C., and Prochaska, J.D. Toward a comprehensive, theoretical model of change: Stages of change and addictive behavior. In: Miller, W.R., and Heather, N., eds. Treating Addictive Behaviors. 2d ed. New York: Plenum Press, 1998. pp. 3–24.
  252. DiMartini A, Day N, Lane T, Beisler A T, Dew M A, Anton R. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcoholism: Clinical and Experimental Research. 2001;27(12):1729–1733.
  253. Dinges M M, Oetting E R. Similarity in drug use patterns between adolescents and their friends. Adolescence. 1993;28(110):253–266. [PubMed: 8317274]
  254. Donald P J. Advanced malignancies in the young marijuana smoker. Advances in Experimental Medicine and Biology. 1991;288:33–46. [PubMed: 1950738]
  255. D'Onofrio G, Rathlev N K, Ulrich A S, Fish S S, Freeland E S. Lorazepam for the prevention of recurrent seizures related to alcohol. New England Journal of Medicine. 1999;340(12):915–919. [PubMed: 10094637]
  256. Dorus W, Ostrow D G, Anton R, Cushman P, Collins J F, Schaefer M, Charles H L, Desai P, Hayashida M, Malkerneker U. Lithium treatment of depressed and nondepressed alcoholics. Journal of the American Medical Association. 1989;262(12):1646–1652. [PubMed: 2504944]
  257. Downes M A, Whyte I M. Amphetamine-induced movement disorder. Emergency Medicine Australasia. 2005;17(3):277–280. [PubMed: 15953231]
  258. Drake R E, Essock S M, Shaner A, Carey K B, Minkoff K, Kola L, Lynde D, Osher F C, Clark R E, Rickards L. Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services. 2001;52(4):469–476. [PubMed: 11274491]
  259. Drake R E, Mueser K T. Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin. 2000;26(1):105–118. [PubMed: 10755672]
  260. Drake R E, Osher F C, Wallach M A. Alcohol use and abuse in schizophrenia: A prospective community study. Journal of Nervous and Mental Disease. 1989;177(7):408–414. [PubMed: 2746194]
  261. Drozdick J III, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. American Journal of Obstetrics and Gynecology. 2002;187(5):1184–1188. [PubMed: 12439500]
  262. Dupont I, Bodenez P, Berthou F, Simon B, Bardou L G, Lucas D. Cytochrome P-450 2E1 activity and oxidative stress in alcoholic patients. Alcohol and Alcoholism. 2000;35(1):98–103. [PubMed: 10684785]
  263. Duseja A, Sachdev A, Dhiman R K, Chawla Y K. Helicobacter pylori and hepatic encephalopathy. Indian Journal of Gastroenterology. 2003;22(Suppl 2):S31–32. [PubMed: 15025251]
  264. Duyff, R.L. The American Dietetic Association's Complete Food and Nutrition Guide. Minneapolis, MN: Chronimed Publishing, 1996.
  265. Earnest M P, Feldman H, Marx J A, Harris J A, Biletch M, Sullivan L P. Intracranial lesions shown by CT scans in 259 cases of first alcohol-related seizures. Neurology. 1988;38(10):1561–1565. [PubMed: 3419599]
  266. Eickelberg, S.J., and Mayo-Smith, M.F. Management of sedative-hypnotic intoxication and withdrawal. In: Graham, A.W., and Wilford, B.B., eds. Principles of Addiction Medicine. 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998. pp. 441–456.
  267. Elderly Alcoholic Men and Women in Treatment. Paper presented at the Research Society on Alcoholism Annual Scientific Meeting, San Diego, California, 1992.
  268. Elman I, D'Ambra M N, Krause S, Breiter H, Kane M, Morris R, Tuffy L, Gastfriend D R. Ultrarapid opioid detoxification: Effects on cardiopulmonary physiology, stress hormones and clinical outcomes. Drug and Alcohol Dependence. 2001;61(2):163–172. [PubMed: 11137281]
  269. Ernst M, Moolchan E T, Robinson M L. Behavioral and neural consequences of prenatal exposure to nicotine. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;40(6):630–641. [PubMed: 11392340]
  270. Etter J F, Perneger T V. Effectiveness of a computer-tailored smoking cessation program: A randomized trial. Archives of Internal Medicine. 2001;161(21):2596–2601. [PubMed: 11718591]
  271. Evans A C, Raistrick D. Phenomenology of intoxication with toluene-based adhesives and butane gas. British Journal of Psychiatry. 1987;150:769–773. [PubMed: 3651728]
  272. Fagerstrom, K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 62 Suppl 2(1):9, 2002.
  273. Fagerstrom K O. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addictive Behaviors. 1978;3(3–4):235–241. [PubMed: 735910]
  274. Fagerstrom K O, Schneider N G. Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire. Journal of Behavioral Medicine. 1989;12(2):159–182. [PubMed: 2668531]
  275. Federal Bureau of Prisons. Federal Bureau of Prisons Clinical Practice Guidelines: Detoxification of Chemically Dependent Inmates, December, 2000. Washington, DC: U.S. Bureau of Prisons, 2000. http://www.nicic.org/pubs/2000/016554.pdf[Accessed April 4, 2002].
  276. Fehr B J, Wenstein S P, Sterling R C, Gottheil E. “As soon as possible”: An initial treatment engagement strategy. Substance Abuse. 1991;12(4):183–189.
  277. Fellows, J.L., Trosclair, A., and Adams, E.K. Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995-1999. Morbidity and Mortality Weekly Report Atlanta, GA: Centers for Disease Control and Prevention, 4-12-2002. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5114a2.htm[Accessed June 27, 2002].
  278. Fenster, L.F. Alcohol and disorders of the gastrointestinal system. In: Estes, N.J., and Heinemann, M.E., eds. Alcoholism: Development, Consequences, and Interventions. St. Louis, MO: C.V. Mosby Company, 1982. pp. 136–143.
  279. Fenster, L.F. Alcohol and disorders of the gastrointestinal system. In: Estes, N.J., and Heinemann, M.E., eds. Alcoholism Development, Consequences and Interventions. 3d ed. St. Louis, MO: C.V. Mosby, 1986. pp. 145–152.
  280. Ferguson F N. Stake theory as an explanatory device in Navajo alcoholism treatment response. Human Organization. 1976;35(1):65–78. [PubMed: 1028744]
  281. Fergusson D M, Horwood L J, Beautrais A L. Is sexual orientation related to mental health problems and suicidality in young people? Archives of General Psychiatry. 1999;56(10):876–880. [PubMed: 10530626]
  282. Fernandez-Sola J, Nicolas-Arfelis J M. Gender differences in alcoholic cardiomyopathy. The Journal of Gender-Specific Medicine. 2002;5(1):41–47. [PubMed: 11859686]
  283. Fine, J., and Miller, N.S. Evaluation and acute management of psychotic symptomatology in alcohol and drug addictions. In: Miller, N.S., and Stimmel, B., eds. Comorbidity of Addictive and Psychiatric Disorders. New York: Haworth Medical Press, 1993.
  284. Fingerhood M I, Jasinski D R, Sullivan J T. Prevalence of hepatitis C in a chemically dependent population. Archives of Internal Medicine. 1993;153(17):2025–2030. [PubMed: 8357288]
  285. Finigan, M. Societal Outcomes and Cost Savings of Drug and Alcohol Treatment in the State of Oregon. Salem, OR: Office of Alcohol and Drug Abuse Programs, Oregon Department of Human Resources, and Governor's Council on Alcohol and Drug Abuse Programs, 1996.
  286. Finn P. Addressing the needs of cultural minorities in drug treatment. Journal of Substance Abuse Treatment. 1994;11(4):325–337. [PubMed: 7966503]
  287. Finnegan L P. Treatment issues for opioid-dependent women during the perinatal period. Journal of Psychoactive Drugs. 1991;23(2):191–201. [PubMed: 1765892]
  288. Finnegan L P, Hagan T, Kaltenbach K A. Scientific foundation of clinical practice: Opiate use in pregnant women. Bulletin of the New York Academy of Medicine. 1991;67(3):223–239. [PMC free article: PMC1807935] [PubMed: 1868275]
  289. Finnegan, L.P., and Wapner, R.J. Narcotic addiction in pregnancy. In: Niebyl, J.R., ed. Drug Use in Pregnancy. 2d ed. Philadelphia: Lea and Febiger, 1988. pp. 203–222.
  290. Fiore, M.C., Bailey, W.C., Cohen, S.J., Dorfman, S.F., Goldstein, M.G., Gritz, E.R., Heyman, R.B., Jaen, C.R., Kottke, T.E., Lando, H.A., Mecklenburg, R.E., Mullen, P.D., Nett, L.M., Robinson, L., Stitzer, M.L., Tommasello, A.C., Villejo, L., and Wewers, M.E. Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians. Rockville, MD: Public Health Service, 2000b. http://www.surgeongeneral.gov/tobacco/tobaqrg.htm[Accessed June 4, 2002].
  291. Fiore, M.C., Bailey, W.C., Cohen, S., Dorfman, S.F., Goldstein, M., Gritz, E.R., Heyman, R.B., Jaen, C.R., Kottke, T.E., Lando, H.A., Mecklenburg, R.E., Mullen, P.D., Nett, L.M., Robinson, L., Stitzer, M.L., Tommasello, A.C., Villejo, L., Wewers, M.E., Baker, T., Fox, D.M., and Hasselblad, V. Treating Tobacco Use and Dependence: A Clinical Practice Guideline. Rockville, MD: Public Health Service, 2000a.
  292. Fiorentine R, Nakashima J, Anglin M D. Client engagement in drug treatment. Journal of Substance Abuse Treatment. 1999;17(3):199–206. [PubMed: 10531626]
  293. First, M.B., Frances, A., and Pincus, H.A. DSM-IV-TR Handbook of Differential Diagnosis. Washington, DC: American Psychiatric Press, 2002.
  294. Fischer G, Johnson R E, Eder H, Jagsch R, Peternell A, Weninger M, Langer M, Aschauer H N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000;95(2):239–244. [PubMed: 10723852]
  295. Flynn P M, Porto J V, Rounds-Bryant J, Kristiansen P L. Costs and Benefits of Methadone Treatment in DATOS—Part 1: Discharged versus Continuing Patients. Journal of Maintenance in the Addictions. 2003;2(1/2):129–150.
  296. Fontaine K R, Cheskin L J, Carriero N J, Jefferson L, Finley C J, Gorelick D A. Body mass index and effects of refeeding on liver tests in drug-dependent adults in a residential research unit. Journal of the American Dietetic Association. 2001;101(12):1467–1469. [PubMed: 11762745]
  297. Ford, W.E. Understanding the Purchase of Outcome in Substance Abuse Treatment. Rockville, MD: Indian Health Service, 2000. http://www.ihs.gov/MedicalPrograms/Alcohol/download/purchase.pdf[Accessed July 15, 2002].
  298. Foster J H, Marshall E J, Peters T J. Outcome after in-patient detoxification for alcohol dependence: A naturalistic comparison of 7 versus 28 days stay. Alcohol and Alcoholism. 2000;35(6):580–586. [PubMed: 11093965]
  299. Fox C H. Cocaine use in pregnancy. Journal of the American Board of Family Practice. 1994;7(3):225–228. [PubMed: 8059626]
  300. Frances, R.J., and Miller, S.I., eds. Clinical Textbook of Addictive Disorders. 2d ed. New York: Guilford Press, 1998.
  301. French, M.T. Drug Abuse Treatment Cost Analysis Program (DATCAP): Program Version. 8th ed. Miami, FL: University of Miami, 2003a. http://www.datcap.com/program.htm[Accessed January 15, 2005].
  302. French, M.T. Drug Abuse Treatment Cost Analysis Program (DATCAP): User's Manual. 8th ed. Miami, FL: University of Miami, 2003b. http://www.datcap.com/usersmanual.htm[Accessed January 15, 2005].
  303. French M T, Dunlap L J, Zarkin G A, McGeary K A, McLellan A T. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment. 1997;14(5):445–455. [PubMed: 9437614]
  304. French M T, Roebuck M C, McLellan A T, Sindelar J L. Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services? Journal of Substance Abuse. 2000;12(4):341–361. [PubMed: 11452838]
  305. French S A, Jefferey R W, Klesges L M, Forster J L. Weight concerns and change in smoking behavior over two years in a working population. American Journal of Public Health. 1995;85(5):720–722. [PMC free article: PMC1615425] [PubMed: 7733437]
  306. Fuller R K, Gordis E. Refining the treatment of alcohol withdrawal. Journal of the American Medical Association. 1994;272(7):557–558. [PubMed: 8046812]
  307. Galanter M, Keller D S, Dermatis H, Egelko S. The impact of managed care on substance abuse treatment: A report of the American Society of Addiction Medicine. Journal of Addictive Diseases. 2000;19(3):13–34. [PubMed: 11076117]
  308. Ganrot P O. Variation of the concentrations of some plasma proteins in normal adults, in pregnant women and in newborns. Scandinavian Journal of Clinical and Laboratory Investigation Supplementum. 1972;124:83–88. [PubMed: 4114362]
  309. Garber, A.J. Diabetes mellitus. In: Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby, 1994. pp. 1391–1424.
  310. Garbis, H., and McElhatton, P.R. Psychotropic, sedative-hypnotic and Parkinson drugs. In: Drugs During Pregnancy and Lactation; Handbook of Prescription Drugs and Comparative Risk Assessment: With Updated Information on Recreational Drugs. New York: Elsevier, 2001. pp. 182–191.
  311. Gariti P, Auriacombe M, Incmikoski R, McLellan A T, Patterson L, Dhopesh V, Mezochow J, Patterson M, O'Brien C. A randomized double-blind study of neuroelectric therapy in opiate and cocaine detoxification. Journal of Substance Abuse. 1992;4(3):299–308. [PubMed: 1458046]
  312. Garro A J, Lieber C S. Alcohol and cancer. Annual Review of Pharmacology and Toxicology. 1990;30:219–249.
  313. Garvey R, Fitzmaurice B. Withdrawal delirium with dance drug “liquid ecstasy” (GHB). Irish Journal of Psychological Medicine. 2004;21(2):73–75.
  314. Gastfriend, D.R. When a substance use disorder is the cause of treatment resistance. In: Pollack, M.H., and Otto, M.W., eds. Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies. New York: Guilford Press, 1996. pp. 329–354.
  315. Gastfriend D R, Lu S H, Sharon E. Placement matching: Challenges and technical progress. Substance Use and Misuse. 2000;35(12–14):2191–2213. [PubMed: 11138721]
  316. Gastfriend D R, McLellan A T. Treatment matching: Theoretic basis and practical implications. Medical Clinics of North America. 1997;81(4):945–966. [PubMed: 9222262]
  317. Gatch M B, Lal H. Pharmacological treatment of alcoholism. Progress in Neuropsychopharmacology and Biological Psychiatry. 1998;22(6):917–944.
  318. Gates, D. Medicaid Financing of Alcohol and Drug Abuse Treatment for Pregnant Women, Mothers, and Their Children. Washington, DC: National Health Law Program, 1992.
  319. Gawin F H, Kleber H D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Archives of General Psychiatry. 1986;43:107–118. [PubMed: 3947206]
  320. Gelenberg, A.J., and Bassuk, E.L., eds. The Practitioner's Guide to Psychoactive Drugs. 4th ed. New York: Plenum Medical Book Co., 1997.
  321. Geller, A. Neurological effects. In: Graham, A.W., and Wilford, B.B., eds. Principles of Addiction Medicine. 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998. pp. 775–792.
  322. Gerstein, D.R., Johnson, R.A., Harwood, H., Fountain, D., Suter, N., and Malloy, K. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento, CA: Department of Alcohol and Drug Programs, 1994. http://www.adp.cahwnet.gov/RC/pdf/caldata.pdf[Accessed April 9, 2002].
  323. Giannini A J, Miller N, Kocjan D K. Treating steroid abuse: A psychiatric perspective. Clinical Pediatrics. 1991;30(9):538–542. [PubMed: 1804586]
  324. Gill K, Eagle Elk M, Liu Y, Deitrich R A. Examination of ALDH2 genotypes, alcohol metabolism and the flushing response in Native Americans. Journal of Studies on Alcohol. 1999;60(2):149–158. [PubMed: 10091951]
  325. Giovino G A, Henningfield J E, Tomar S L, Escobedo L G, Slade J. Epidemiology of tobacco use and dependence. Epidemiologic Reviews. 1995;17(1):48–65. [PubMed: 8521946]
  326. Glover E D, Glover P N. Pharmacologic treatments for the nicotine dependent smoker. American Journal of Health Behavior. 2001;25(3):179–182. [PubMed: 11322615]
  327. Glover, E.D., Nilsson, F., Westin, A., and Glover, P.N. “Glover-Nilsson Smoking Behavioral Questionnaire (GN-SBQ).” Paper presented at the 8th Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA, 2002.
  328. Gold C G, Cullen D J, Gonzales S, Houtmeyers D, Dwyer M J. Rapid opioid detoxification during general anesthesia: A review of 20 patients. Anesthesiology. 1999;91(6):1639–1647. [PubMed: 10598605]
  329. Gold M S, Dackis C A, Washton A M. The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Advances in Alcohol and Substance Abuse. 1984;3(3):19–39. [PubMed: 6388273]
  330. Gold M S, Redmond D E Jr, Kleber H D. Clonidine blocks acute opiate-withdrawal symptoms. Lancet. 1978;2(8090):599–602. [PubMed: 80526]
  331. Golden S A, Sakhrani D L. Unexpected delirium during Rapid Opioid Detoxification (ROD). Journal of Addictive Diseases. 2004;23(1):65–75. [PubMed: 15077841]
  332. Goldsmith R J. Overview of psychiatric comorbidity: Practical and theoretical considerations. Psychiatric Clinics of North America. 1999;22(2):331–349. [PubMed: 10385937]
  333. Goldstein, G. Recovery, treatment and rehabilitation in chronic alcoholics. In: Parsons, O.A., Butters, N., and Nathan, P.E., eds. Neuropsychology of Alcoholism: Implications for Diagnosis and Treatment. New York: Guilford Press, 1987.
  334. Gondolf E, Coleman K, Roman S. Clinical-based vs. insurance-based recommendations for substance abuse treatment level. Substance Use and Misuse. 1996;31(9):1101–1116. [PubMed: 8853232]
  335. Goodman L, Koss M, Russo N. Violence against women: Physical and mental health effects. Part I: Research. Applied and Preventive Psychology. 1993;2:79–89.
  336. Gorelick D A, Gardner E L, Xi Z X. Agents in development for the management of cocaine abuse. Drugs. 2004;64(14):1547–1573. [PubMed: 15233592]
  337. Gossop M, Keaney F, Stewart D. A short alcohol withdrawal scale (SAWS): Development and psychometric properties. Addiction Biology. 2002;7:37–43. [PubMed: 11900621]
  338. Gottheil E, Sterling R C, Weinstein S P. Pretreatment dropouts: Characteristics and outcomes. Journal of Addictive Diseases. 1997;16(2):1–14. [PubMed: 9083821]
  339. Gottschalk P C, Jacobsen L K, Kosten T R. Current concepts in pharmacotherapy of substance abuse. Current Psychiatry Reports. 1999;1(2):172–178. [PubMed: 11122921]
  340. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H J, Fimm B, Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). Journal of Neurology, Neurosurgery, and Psychiatry. 2000;68(6):719–725.
  341. Grabowski J, Rhoades H, Schmitz J, Stotts A, AnnDaruzska L, Creson D, Moeller F G. Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial. Journal of Clinical Psychopharmacology. 2001;21(5):522–526. [PubMed: 11593078]
  342. Graham, A.W., Schultz, T.K., Mayo-Smith, M.F., Ries, R.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003.
  343. Graham, A.W., Schultz, T.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998.
  344. Greenfeld, L.A., and Snell, T.L. Women Offenders. Bureau of Justice Statistics Special Report. NCJ 175688. Washington, DC: Bureau of Justice Statistics, 1999. http://www.ojp.usdoj.gov/bjs/pub/pdf/wo.pdf[Accessed February 28, 2003].
  345. Greenspon A J, Schaal S F. The “holiday heart”: Electrophysiologic studies of alcohol effects in alcoholics. Annals of Internal Medicine. 1983;98(2):135–139. [PubMed: 6824246]
  346. Greer B G. Substance abuse among people with disabilities: A problem of too much accessibility. Journal of Rehabilitation. 1986;14(1):34–37.
  347. Griffith J D, Joe G W, Chatham L R, Simpson D D. The development and validation of a Simpatia Scale for Hispanics entering drug treatment. Hispanic Journal of Behavioral Sciences. 1998;20(4):468–482.
  348. Gritz E R, Klesges R C, Meyers A W. The smoking and body weight relationship: Implications for intervention and post-cessation weight control. Annals of Behavioral Medicine. 1989;11(4):144–153.
  349. Gross M M, Rosendlatt S M, Lewis E, Chartof S, Malenowski B. Acute alcoholic psychoses in related syndromes: Psychosocial and clinical characteristics and their implications. British Journal of Addiction. 1972;65:15–31.
  350. Gulliver S B, Rohsenow D J, Colby S M, Dey A N, Abrams D B, Niaura R S, Monti P M. Interrelationship of smoking and alcohol dependence, use and urges to use. Journal of Studies on Alcohol. 1995;56(2):202–206. [PubMed: 7760567]
  351. Gupta R, Espinal M A, Raviglione M C. Tuberculosis as a major global health problem in the 21st century: A WHO perspective. Seminars in Respiratory and Critical Care Medicine. 2004;25(3):245–253. [PubMed: 16088467]
  352. Gupta S K, Hwang S S, Causey D, Rolf C N, Gorsline J. Comparison of the nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) and half-hourly cigarette smoking. Journal of Clinical Pharmacology. 1995;35(10):985–989. [PubMed: 8568016]
  353. Guthmann, D.S. An Analysis of Variables That Impact Treatment Outcomes of Chemically Dependent Deaf and Hard of Hearing Individuals. Minneapolis, MN: Minnesota Chemical Dependency Program for Deaf and Hard of Hearing Individuals, 2002. http://www.mncddeaf.org/articles/analysis_ad.htm[Accessed November 1, 2002].
  354. Hall S M, Tunstall C D, Vila K L, Duffy J. Weight gain prevention and smoking cessation: Cautionary findings. American Journal of Public Health. 1992;82(6):799–803. [PMC free article: PMC1694191] [PubMed: 1585959]
  355. Haller D L, Knisely J S, Dawson K S, Schnoll S H. Perinatal substance abusers. Psychological and social characteristics. Journal of Nervous and Mental Disease. 1993;181(8):509–513. [PubMed: 8360642]
  356. Handelsman L, Cochrane K J, Aronson M J, Ness R, Rubinstein K J, Kanof P D. Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse. 1987;13(3):293–308. [PubMed: 3687892]
  357. Haney M, Ward A S, Comer S D, Foltin R W, Fischman M W. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology. 1999;141(4):395–404. [PubMed: 10090647]
  358. Harrison, P.M., and Beck, A.J. Prison and jail inmates at midyear 2004. Bureau of Justice Statistics Bulletin (April):NCJ 208801. Washington, DC: Bureau of Justice Statistics, 2005. http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim04.pdf[Accessed April 27, 2005].
  359. Hayashida M. An overview of outpatient and inpatient detoxification. Alcohol Health and Research World. 1998;22(1):44–46. [PubMed: 15706732]
  360. Heath, D.B. American Indians and alcohol: Epidemiological and sociocultural relevance. In: Spiegler, D., Tate, D., and Aitkin, S., eds. Alcohol Use Among US Ethnic Minorities. Proceedings of a Conference on the Epidemiology of Alcohol Use and Abuse Among Ethnic Minority Groups. NIDA Research Monograph 18. DHHS Pub. No. (ADM) 89-1435. Washington, DC: U.S. Government Printing Office, 1989. pp. 207–222.
  361. Heatherton T, Kozlowski L, Frecker R, Fagerstrom K O. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction. 1991;86(9):1119–1127. [PubMed: 1932883]
  362. Hedlund L, Wahlstrom G. The effect of diazepam on voluntary ethanol intake in a rat model of alcoholism. Alcohol and Alcoholism. 1998;33(3):207–219. [PubMed: 9632046]
  363. Helms, J.E., and Parham, T.A. The racial identity attitude scale (RAIS). In: Jones, R.L., ed. Handbook of Tests and Measurements for Black Populations. Hampton, VA: Cobb and Henry, 1996. pp. 167–174.
  364. Helzer, J.E. Psychiatric diagnosis, family psychiatric history. In: Rounsaville, B.J., Tims, F., Horton, A.M., and Sowder, B.J., eds. Diagnostic Source Book on Drug Abuse Research and Treatment. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse, 1993.
  365. Helzer, J.E., Bucholz, K., and Robins, L.N. Five communities in the United States: Results of the Epidemiologic Catchment Area Survey. In: Helzer, J.E., and Canino, G.J., eds. Alcoholism in North America, Europe, and Asia. New York: Oxford University Press, 1992. pp. 71–95.
  366. Helzer, J.E., and Canino, G., eds. Alcoholism in North America, Europe, and Asia. New York: Oxford University Press, 1992.
  367. Henningfield J E, Chait L D, Griffiths R R. Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism. Psychopharmacology. 1984;82(1–2):1–5. [PubMed: 6420817]
  368. Higgins S T, Delaney D D, Budney A J, Bickel W K, Hughes J R, Foerg F, Fenwick J W. A behavioral approach to achieving initial cocaine abstinence. American Journal of Psychiatry. 1991;148(9):1218–1224. [PubMed: 1883001]
  369. Hillbom M, Numminen H. Alcohol and stroke: Pathophysiologic mechanisms. Neuroepidemiology. 1998;17(6):281–287. [PubMed: 9778594]
  370. Hillbom M E, Hjelm-Jager M. Should alcohol withdrawal seizures be treated with anti-epileptic drugs? Acta Neurologica Scandinavica. 1984;69(1):39–42. [PubMed: 6702419]
  371. Hitsman B, Pingitore R, Spring B, Mahableshwarkar A, Mizes J S, Segraves K A, Kristeller J L, Xu W. Antidepressant pharmacotherapy helps some cigarette smokers more than others. Journal of Consulting and Clinical Psychology. 1999;67(4):547–554. [PubMed: 10450625]
  372. Ho A, Dole V P. Pain perception in drug-free and in methadone-maintained human ex-addicts. Proceedings of the Society for Experimental Biology and Medicine. 1979;162(3):392–395. [PubMed: 515020]
  373. Hoffman, N.G., and American Society of Addiction Medicine. Adult Criteria Task Force, Adolescent Criteria Task Force. ASAM Patient Placement Criteria for the Treatment of Psychoactive Substance Use Disorders. Washington, DC: American Society of Addiction Medicine, 1991.
  374. Hoffman N G, Miller N S. Treatment outcomes for abstinence based programs. Psychiatric Annals. 1992;22(8):402–408.
  375. Hoffman R S, Hollander J E. Evaluation of patients with chest pain after cocaine use. Critical Care Clinics. 1997;13(4):809–828. [PubMed: 9330842]
  376. Holder H D. Cost benefits of substance abuse treatment: An overview of results from alcohol and drug abuse. Journal of Mental Health Policy and Economics. 1998;1(1):23–29. [PubMed: 11964488]
  377. Holder H D, Blose J O. Alcoholism treatment and total health care utilization and costs. A four-year longitudinal analysis of Federal employees. Journal of the American Medical Association. 1986;256(11):1456–1460. [PubMed: 3747063]
  378. Holder H D, Blose J O. Mental health treatment and the reduction of health care costs: A four-year study of U.S. Federal employees enrollment with the Aetna Life Insurance Company. Advances in Health Economics and Health Services Research. 1987;8(157–74):157–174. [PubMed: 10292339]
  379. Holder H D, Boyd G, Howard J, Flay B, Voas R, Grossman M. Alcohol-problem prevention research policy: The need for a phases research model. Journal of Public Health Policy. 1995;16(3):324–346. [PubMed: 7499514]
  380. Hollander J E. The management of cocaine-associated myocardial ischemia. New England Journal of Medicine. 1995;333(19):1267–1272. [PubMed: 7566005]
  381. Hook E W. Management of syphilis in human immunodeficiency virus-infected patients. American Journal of Medicine. 1992;93:477–479. [PubMed: 1442849]
  382. Hopewell, P.C., and Small, P.M. Tuberculosis and nontuberculous mycobaterial infections. In: Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby, 1994. pp. 2193–2212.
  383. Hopkins, H.S., and Gelenberg, A.J. Bipolar disorder. In: Gelenberg, A.J., and Bassuk, E.L., eds. The Practitioner's Guide to Psychoactive Drugs. New York: Plenum Medical Book Co, 1997. pp. 123–151.
  384. Horvath A O, Luborsky L. The role of the therapeutic alliance in psychotherapy. Journal of Consulting and Clinical Psychology. 1993;61(4):561–573. [PubMed: 8370852]
  385. House R M, Pinyuchon M. Counseling Thai Americans: An emerging need. Journal of Multicultural Counseling and Development. 1998;26(3):194–204.
  386. Hser Y I, Polinsky M L, Maglione M, Anglin M D. Matching clients' needs with drug treatment services. Journal of Substance Abuse Treatment. 1999;16(4):299–305. [PubMed: 10349602]
  387. Hsu L C, Tani K, Fujiyoshi T, Kurachi K, Yoshida A. Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2. Proceedings of the National Academy of Sciences of the United States of America. 1985;82(11):3771–3775. [PMC free article: PMC397869] [PubMed: 2987944]
  388. Huff, R.M., and Kline, M.V. Tips for working with Hispanic populations. In: Huff, R.M., and Kline, M.V., eds. Promoting Health in Multicultural Populations: A Handbook for Practitioners. Thousand Oaks, CA: Sage Publications, 1999. pp. 189–197.
  389. Hughes J R. Dependence potential and abuse liability of nicotine replacement therapies. Biomedicine and Pharmacotherapy. 1989;43(1):11–17.
  390. Hughes, J.R. Combining behavioral therapy and pharmacotherapy for smoking cessation: An update. In: Onken, L.S., Blaine, J.D., and Boren, J.J., eds. Integrating Behavioral Therapies with Medications in the Treatment of Drug Dependence. NIDA Research Monograph 150. NIH Publication No. 95-3899. Rockville, MD: National Institute on Drug Abuse, 1995. pp. 92–109.
  391. Hughes J R, Hatsukami D K. The nicotine withdrawal syndrome: A brief review and update. International Journal of Smoking Cessation. 1992;1:21–26.
  392. Hughes J R, Lesmes G R, Hatsukami D K, Richmond R L, Lichtenstein E, Jorenby D E, Broughton J O, Fortmann S P, Leischow S J, McKenna J P, Rennard S I, Wadland W C, Heatley S A. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine and Tobacco Research. 1999;1(2):169–174. [PubMed: 11072398]
  393. Hughes T L, Wilsnack S C. Use of alcohol among lesbians: Research and clinical implications. American Journal of Orthopsychiatry. 1997;67(1):20–36. [PubMed: 9034019]
  394. Humphreys K, Moos R H. Reduced substance-abuse-related health care costs among voluntary participants in Alcoholics Anonymous. Psychiatric Services. 1996;47(7):709–713. [PubMed: 8807683]
  395. Hurt R D, Dale L C, Croghan G A, Croghan I T, Gomez-Dahl L C, Offord K P. Nicotine nasal spray for smoking cessation: Pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clinic Proceedings. 1998;73(2):118–125. [PubMed: 9472993]
  396. Hurt R D, Dale L C, Offord K P, Bruce B K, McClain F L, Eberman K M. Inpatient treatment of severe nicotine dependence. Mayo Clinic Proceedings. 1992;67(9):823–828. [PubMed: 1434925]
  397. Hurt R D, Eberman K M, Croghan I T, Offord K P, Davis L J Jr, Morse R M, Palmen M, Bruce B K. Nicotine dependence treatments during inpatient treatment for other addictions: A prospective intervention trial. Alcoholism: Clinical and Experimental Research. 1994;18(4):867–872.
  398. Institute on Black Chemical Abuse. Overview of Cultural Sensitivity and Specificity: IBCA Definitions and Perspectives. Minneapolis, MN: Institute on Black Chemical Abuse, 1992.
  399. Ivey K J. Drugs, gastritis, and peptic ulcer. Journal of Clinical Gastroenterology. 1981;3(suppl 2):29–34. [PubMed: 7320467]
  400. Ja, D.Y., and Aoki, B. Substance abuse treatment: Cultural barriers in the Asian American community. In: Organista, P.B., Chun, K.M., and Marin, G., eds. Readings in Ethnic Psychology. New York: Routledge, 1998. pp. 386–401.
  401. Jackson M S, Stephens R C, Smith R L. Afrocentric treatment in residential substance abuse care: The Iwo San. Journal of Substance Abuse Treatment. 1997;14(1):87–92. [PubMed: 9218242]
  402. James W. Examining racial and ethnic differences in Asian adolescent drug use: The contributions of culture, background and lifestyle. Drugs: Education, Prevention, and Policy. 1997;4(1):39–52.
  403. Janicak, P.G. Principles and Practice of Psychopharmacotherapy. Baltimore: Williams & Wilkins, 1993.
  404. Jauhar P, Anderson J. Is daily single dosage of diazepam as effective as chlordiazepoxide in divided doses in alcohol withdrawal—a pilot study. Alcohol and Alcoholism. 2000;35(2):212–214. [PubMed: 10787400]
  405. Javors, M.A., Pichot, J.T., King, T.S., and Anton, R.S. Search for biological markers. In: Johnson, B.A., and Roache, J.D., eds. Drug Addiction and its Treatment: Nexus of Neuroscience and Behavior. Philadelphia: Lippincott-Raven, 1997. pp. 205–231.
  406. Joe G W, Brown B S, Simpson D. Psychological problems and client engagement in methadone treatment. Journal of Nervous and Mental Disease. 1995;183(11):704–710. [PubMed: 7595433]
  407. Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitzer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine. 2000;343(18):1290–1297. [PubMed: 11058673]
  408. Johnson R E, Jones H E, Jasinski D R, Svikis D S, Haug N A, Jansson L M, Kissin W B, Alpan G, Lantz M E, Cone E J, Wilkins D G, Golden A S, Huggins G R, Lester B M. Buprenorphine treatment of pregnant opioid-dependent women: Maternal and neonatal outcomes. Drug and Alcohol Dependence. 2001;63(1):97–103. [PubMed: 11297835]
  409. Johnston, L.D., O'Malley, P.M., and Bachman, J.G. National Survey Results on Drug Use From the Monitoring the Future Study, 1975-1995: Volume II, College Students and Young Adults. NIH Publication No. 01-4925. Bethesda, MD: National Institute on Drug Abuse, 1997.
  410. Jones A W, Andersson L. Influence of age, gender, and blood-alcohol concentration on the disappearance rate of alcohol from blood in drinking drivers. Journal of Forensic Science. 1996;41(6):922–926.
  411. Jones A W, Sternebring B. Kinetics of ethanol and methanol in alcoholics during detoxification. Alcohol and Alcoholism. 1992;27(6):641–647. [PubMed: 1292437]
  412. Jones H E, Balster R L. Inhalant abuse in pregnancy. Obstetrics and Gynecology Clinics of North America. 1998;25(1):153–167. [PubMed: 9547765]
  413. Jones H E, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug and Alcohol Dependence. 2001a;61:297–306. [PubMed: 11164694]
  414. Jones H E, Johnson R E. Pregnancy and substance abuse. Current Opinion in Psychiatry. 2001;14:187–193.
  415. Jones, H.E., Johnson, R.E., and Tuten, M. Methadone Detoxification of Pregnant Opiate Addicted Women: Safety and Efficacy. 2001b.
  416. Jones, H.E., Velez, M.L., McCaul, M.E., and Svikis, D.S. Special treatment issues for women. In: Strain, E.C., and Stitzer, M., eds. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press, 1999. pp. 251–280.
  417. Jorenby D E, Leischow S J, Nides M A, Rennard S I, Johnston J A, Hughes A R, Smith S S, Muramoto M L, Daughton D M, Doan K, Fiore M C, Baker T B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine. 1999;340(9):685–691. [PubMed: 10053177]
  418. Kaiser Family Foundation and Health Research and Educational Trust. Employer Health Benefits 2003 Annual Survey. Menlo Park, CA: Henry J. Kaiser Family Foundation, 2003. http://www.kff.org/insurance/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=20672[Accessed January 7, 2005].
  419. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: Effects and management. Obstetrics and Gynecology. 1998;25(1):139–151. [PubMed: 9547764]
  420. Kampman K M, Alterman A I, Volpicelli J R, Maany I, Muller E S, Luce D D, Mulholland E M, Parikh G A, Mulvaney F D, Weinrieb R M, O'Brien C P. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychology of Addictive Behaviors. 2001b;15(1):52–59. [PubMed: 11255939]
  421. Kampman K M, Volpicelli J R, Alterman A I, Cornish J, O'Brien C P. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. American Journal of Psychiatry. 2000;157(12):2052–2054. [PubMed: 11097979]
  422. Kampman K M, Volpicelli J R, McGinnis D E, Alterman A I, Weinrieb R M, D'Angelo L, Epperson L E. Reliability and validity of the cocaine selective severity assessment. Addictive Behaviors. 1998;23(4):449–461. [PubMed: 9698974]
  423. Kampman K M, Volpicelli J R, Mulvaney F, Alterman A L, Cornish J, Gariti P, Cnaan A, Poole S, Muller E, Acosta T, Luce D, O'Brien C. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence. 2001a;63(1):69–78. [PubMed: 11297832]
  424. Kandall, S.R. Women and addiction in the United States—1920 to the present. In: Wetherington, C.L., and Roman, A.B., eds. Drug Addiction Research and the Health of the Women. NIH Publication No. 98-4290. Rockville, MD: National Institute on Drug Abuse, 1998. pp. 53–80.
  425. Kandall S R, Albin S, Gartner L M, Lee K S, Eidelman A, Lowinson J. The narcotic-dependent mother: Fetal and neonatal consequences. Early Human Development. 1977;1(2):159–169. [PubMed: 617308]
  426. Kaplan, H.I., Sadock, B.J., and Cancro, R., eds. Comprehensive Textbook of Psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1995.
  427. Kashner T M, Rodell D E, Ogden S R, Guggenheim F G, Karson C N. Outcomes and costs of two VA inpatient treatment programs for older alcoholic patients. Hospital and Community Psychiatry. 1992;43(10):985–989. [PubMed: 1328022]
  428. Kasser, C., Geller, A., Howell, E., and Wartenberg, A. Detoxification: Principles and Protocols. Chevy Chase, MD: American Society of Addiction Medicine, 2000. http://www.asam.org/publ/detoxification.htm[Accessed January 11, 2001].
  429. Kaufman E. Diagnosis and treatment of drug and alcohol abuse in women. American Journal of Obstetrics and Gynecology. 1996;174:21–27. [PubMed: 8572008]
  430. Kazarian, S.S., and Evans, D.R. Cultural Clinical Psychology: Theory, Research, and Practice. New York: Oxford University Press, 1998.
  431. Keilitz I, Hall D. Some statutes governing involuntary outpatient civil commitment. Maryland Law Review. 1985;9(5):378–397.
  432. Keller, M., and Rosenberg, S.S., eds. Alcohol and Health: Report from the Secretary of Health, Education, and Welfare. New York: Scribner, 1973.
  433. Kertesz S G, Horton N J, Friedmann P D, Saitz R, Samet J H. Slowing the revolving door: Stabilization programs reduce homeless persons' substance use after detoxification. Journal of Substance Abuse Treatment. 2003;24(3):197–207. [PubMed: 12810140]
  434. Keso L, Salaspuro M. Inpatient treatment of employed alcoholics: A randomized clinical trial on Hazelden-type and traditional treatment. Alcoholism: Clinical and Experimental Research. 1990;14(4):584–589.
  435. Kessler R C, Barker P R, Colpe L J, Epstein J F, Gfroerer J C, Hiripi E, Howes M J, Normand L T, Mandersheid R W, Walters E E, Zaslavsky A M. Screening for serious mental illness in the general population. Archives of General Psychiatry. 2003;60(2):184–189. [PubMed: 12578436]
  436. Kessler R C, Crum R M, Warner L A, Nelson C B, Schulenberg J, Anthony J C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry. 1997;54(4):313–321. [PubMed: 9107147]
  437. Kessler R C, Nelson C B, McGonagle K A, Edlund M J, Frank R G, Leaf P J. The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. American Journal of Orthopsychiatry. 1996;66(1):17–31. [PubMed: 8720638]
  438. Kessler, R.C., Nelson, C.B., McGonagle, K.A., Liu, J., Swartz, M., and Blazer, D.G. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey. British Journal of Psychiatry Supplement (30):17–30, 1996.
  439. Kienbaum P, Scherbaum N, Thurauf N, Michel M C, Gastpar M, Peters J. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: A comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. Critical Care Medicine. 2000;28(4):969–976. [PubMed: 10809268]
  440. Killen J D, Fortmann S P, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? Experimental and Clinical Psychopharmacology. 1999;7(3):226–233. [PubMed: 10472510]
  441. Kirchner J E, Booth B M, Owen R R, Lancaster A E, Smith G R. Predictors of patient entry into alcohol treatment after initial diagnosis. Journal of Behavioral Health Services and Research. 2000;27(3):339–446. [PubMed: 10932447]
  442. Kleber H D, Topazian M, Gaspari J, Riordan C E, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. American Journal of Drug and Alcohol Abuse. 1987;13(1–2):1–17. [PubMed: 3687878]
  443. Klein M, Calderon S, Hayes B. Abuse liability assessment of neuroprotectants. Annals of the New York Academy of Sciences. 1999;890:515–525. [PubMed: 10668457]
  444. Kleinman B P, Millery M, Scimeca M, Polissar N L. Predicting long-term treatment utilization among addicts entering detoxification: The contribution of help-seeking models. Journal of Drug Issues. 2002;32(1):209–230.
  445. Kleinman, P.H., Woody, G.E., Todd, T.C., Millman, R.B., Kang, S.Y., Kemp, J., and Lipton, D.S. Crack and cocaine abusers in outpatient psychotherapy. In: Onken, L.S., and Blaine, J.D., eds. Psychotherapy and Counseling in the Treatment of Drug Abuse. DHHS Publication No. (ADM) 90-1722. Rockville, MD: National Institute on Drug Abuse, 1990. pp. 24–35.
  446. Klijnsma M P, Cameron M L, Burns T P, McGuigan S M. Outpatient alcohol detoxification outcome after 2 months. Alcohol and Alcoholism. 1995;30(5):669–673. [PubMed: 8554652]
  447. Kline A. Pathways into drug user treatment: The influence of gender and racial/ethnic identity. Substance Use and Misuse. 1996;31(3):323–342. [PubMed: 8834265]
  448. Koenig, L., Denmead, G., Nguyen, R., Harrison, M., and Harwood, H. The Costs and Benefits of Substance Abuse Treatment: Findings from the National Treatment Improvement Evaluation Study (NTIES). Fairfax, VA: Caliber Associates, National Evaluation Data Services, 1999.
  449. Kofoed L, Kania J, Walsh T, Atkinson R M. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. American Journal of Psychiatry. 1986;143(7):867–872. [PubMed: 3087222]
  450. Kofoed L L, Tolson R L, Atkinson R M, Toth R L, Turner J A. Treatment compliance of older alcoholics: An elder-specific approach is superior to “mainstreaming” Journal of Studies on Alcohol. 1987;48(1):47–51. [PubMed: 3821118]
  451. Kolodner G. Ambulatory detoxification as an introduction to treatment. Currents in Alcoholism. 1977;1:311–317.
  452. Kongsakon R, Papadopoulos K I, Saguansiritham R. Mirtazapine in amphetamine detoxification: A placebo-controlled pilot study. International Clinical Psychopharmacology. 2005;20(5):253–256. [PubMed: 16096515]
  453. Kosten T R, McCance-Katz E. New pharmacotherapies. American Psychiatric Press Review of Psychiatry. 1995;14:105–126.
  454. Kosten T R, Rounsaville B J, Kleber H D. Concurrent validity of the Addiction Severity Index. Journal of Nervous and Mental Disease. 1983;171(10):606–610. [PubMed: 6619823]
  455. Kranzler, H.R., and Jaffe, J.H. Pharmacologic interventions for alcoholism. In: Graham, A.W., Schultz, T.K., Mayo-Smith, M.F., Ries, R.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003. pp. 701–720.
  456. Krestan, J. Addiction, power, and powerlessness. In: Krestan, J.A., ed. Bridges To Recovery: Addiction, Family Therapy, and Multicultural Treatment. New York: Free Press, 2000. pp. 15–44.
  457. Kuhnz W, Koch S, Helge H, Nau H. Primidone and phenobarbital during lactation period in epileptic women: Total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Developmental Pharmacology and Therapeutics. 1988;11(3):147–154. [PubMed: 3383727]
  458. Lader M H. Limitations of the use of benzodiazepines in anxiety and insomnia: Are they justified? European Neuropsychopharmacology. 1999;9(Suppl 6):S399–S405. [PubMed: 10622686]
  459. Lahti A C, Weiler M A, Michaelidis B A, Parwani A, Tamminga C A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455–467. [PubMed: 11557159]
  460. Lambert M T. Linking mental health and addiction services: A continuity-of-care team model. Journal of Behavioral Health Services and Research. 2002;29(4):433–444. [PubMed: 12404937]
  461. Landau J, Garrett J, Shea R R, Stanton M D, Brinkman-Sull D, Baciewicz G. Strength in numbers: The ARISE method for mobilizing family and network to engage substance abusers in treatment. A Relational Intervention Sequence for Engagement. American Journal of Drug and Alcohol Abuse. 2000;26(3):379–398. [PubMed: 10976664]
  462. Lapham S, Hall M, Snyder J, Skipper B, McMurray-Avila M, Pulvino S, Kozeny T. Demonstration of a mixed social/medical model detoxification program for homeless alcohol abusers. Contemporary Drug Problems. 1996;23(Summer):301–330.
  463. Lash S J. Increasing participation in substance abuse aftercare treatment. American Journal of Drug and Alcohol Abuse. 1998;24(1):31–36. [PubMed: 9513628]
  464. Lawson G M, Hurt R D, Dale L C, Offord K P, Croghan I T, Schroeder D R, Jiang N S. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. Journal of Clinical Pharmacology. 1998;38(6):502–509. [PubMed: 9650539]
  465. Lechtenberg R, Worner T M. Seizure risk with recurrent alcohol detoxification. Archives of Neurology. 1990;47(5):535–538. [PubMed: 2334301]
  466. Lechtenberg R, Worner T M. Relative kindling effect of detoxification and non-detoxification admissions in alcoholics. Alcohol and Alcoholism. 1991;26(2):221–225. [PubMed: 1878083]
  467. Lechtenberg R, Worner T M. Total ethanol consumption as a seizure risk factor in alcoholics. Acta Neurologica Scandinavica. 1992;85(2):90–94. [PubMed: 1574994]
  468. Legarda J, Gossop M. A 24-hour inpatient detoxification treatment for heroin addicts: A preliminary investigation. Drug and Alcohol Dependence. 1994;35(2):91–93. [PubMed: 8055740]
  469. Lehman A F, Myers C P, Corty E. Assessment and classification of patients with psychiatric and substance abuse syndromes. 1989. Psychiatric Services. 2000;51(9):1119–1125. [PubMed: 10970913]
  470. Lejoyeux M, Solomon J, Ades J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol and Alcoholism. 1998;33(6):563–575. [PubMed: 9872344]
  471. Lerner, W.D., and Barr, M.A., eds. Handbook of Hospital Based Substance Abuse Treatment. New York: Pergamon Press, 1990.
  472. Lesser, I.M., Smith, M., Poland, R.E., and Lin, K.M. Psychopharmacology and ethnicity. In: Friedman, S., ed. Cultural Issues in the Treatment of Anxiety. New York: Guilford Press, 1997. pp. 199–224.
  473. Levin, S.M., and Greene, J.A., eds. Linking Substance Abuse Treatment and Domestic Violence Services: A Guide for Administrators. Concise Desk Reference Guide. DHHS Publication No. (SMA) 00-3391. Rockville, MD: Center for Substance Abuse Treatment, 2000.
  474. Li J X, Han R, Deng Y P, Chen S Q, Liang J H. Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behavioural Brain Research. 2005;161(1):125–132. [PubMed: 15904719]
  475. Liberto J G, Oslin D W, Ruskin P E. Alcoholism in older persons: A review of the literature. Hospital and Community Psychiatry. 1992;43(10):975–984. [PubMed: 1398581]
  476. Liepman, M.R. Using family influence to motivate alcoholics to enter treatment: The Johnson Institute Intervention approach. In: O'Farrell, T.J., ed. Treating Alcohol Problems: Marital and Family Interventions. New York: Guilford Press, 1993. pp. 54–77.
  477. Linder J D, Monkemuller K E, Raijman I, Johnson L, Lazenby A J, Wilcox C M. Cocaine-associated ischemic colitis. Southern Medical Journal. 2000;93(9):909–913. [PubMed: 11005354]
  478. Liskow B I, Goodwin D W. Pharmacological treatment of alcohol intoxication, withdrawal and dependence: A critical review. Journal of Studies on Alcohol. 1987;48(4):356–370. [PubMed: 2956463]
  479. Livneh H, Male R. Functional limitations: A review of their characteristics and vocational impact. Journal of Rehabilitation. 1993;59(4):44–50.
  480. Loimer N, Lenz K, Schmid R, Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. American Journal of Psychiatry. 1991;148(7):933–935. [PubMed: 2053636]
  481. Loimer N, Schmid R, Presslich O, Lenz K. Naloxone treatment for opiate withdrawal syndrome. British Journal of Psychiatry. 1988;153:851–852. [PubMed: 3256401]
  482. Longabaugh R, Beattie M, Noel N, Stout R, Malloy P. The effect of social investment on treatment outcome. Journal of Studies on Alcohol. 1993;54(4):465–478. [PubMed: 8341050]
  483. Lopez, F. Confidentiality of Patient Records for Alcohol and Other Drug Treatment. Technical Assistance Publication Series 13. DHHS Publication No. (SMA) 99-3321. Rockville, MD: Center for Substance Abuse Treatment, 1994.
  484. Lovejoy, A., Ryan, E.M., Johnson, K., and Tucci, A.S. Federal Funding for Substance Abuse Treatment and Support Services: Sources and Uses. Washington, DC: American Public Health Services Association, 1999.
  485. Luborsky L. A pattern-setting therapeutic alliance study revisited. Psychotherapy Research. 2000;10(1):17–29.
  486. Luborsky, L., Barber, J.P., Siqueland, L., McLellan, A.T., and Woody, G. Establishing a therapeutic alliance with substance abusers. In: Onken, L.S., Blaine, J.D., and Boren, J.J., eds. Beyond the Therapeutic Alliance: Keeping the Drug Dependent Individual in Treatment. NIDA Research Monograph 165. NIH Publication No. 97-4142. Rockville, MD: National Institute on Drug Abuse, 1997. pp. 233–244.
  487. Luborsky, L., Crits-Christoph, P., Mintz, J., and Auerbach, A. Who Will Benefit From Psychotherapy? Predicting Therapeutic Outcomes. New York: Basic Books, 1988.
  488. Lukas, S.E. The pharmacology of steroids. In: Graham, A.W., and Shultz, T.K., eds. Principles of Addiction Medicine. 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998.
  489. Lundgren L, Amodeo M, Schneider R, Ellis M, Fitzgerald T, Stevens R. African-American injection drug users: Association between pre-treatment services and entry into and completion of detoxification. Evaluation and Program Planning. 1999;22(3):259–267.
  490. Mail P D, Johnson S. Boozing, sniffing, and toking: An overview of the past, present, and future of substance use by American Indians. American Indian and Alaska Native Mental Health Research. 1993;5(2):1–33. [PubMed: 8130311]
  491. Malcolm R, Myrick H, Brady K T, Ballenger J C. Update on anticoagulants for the treatment of alcohol withdrawal. American Journal on Addictions. 2001;10(Suppl):16–23. [PubMed: 11268817]
  492. Malcolm R, Myrick H, Roberts J, Wang W, Anton R F, Ballenger J C. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. Journal of General Internal Medicine. 2002;17(5):349–355. [PMC free article: PMC1495040] [PubMed: 12047731]
  493. Malcolm R, Roberts J S, Wang W, Myrick H, Anton R F. Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol. 2000;22(3):159–164. [PubMed: 11163123]
  494. Mancall, P.C. Deadly Medicine: Indians and Alcohol in Early America. Ithaca: Cornell University Press, 1995.
  495. Marantz P R, Linzer M, Feiner C J, Feinstein S A, Kozin A M, Friedland G H. Inability to predict diagnosis in febrile intravenous drug abusers. Annals of Internal Medicine. 1987;106(6):823–828. [PubMed: 3579068]
  496. Margolis, R.D., and Zweben, J.E. Treating Patients with Alcohol and Other Drug Problems: An Integrated Approach. Washington, DC: American Psychological Association, 1998.
  497. Mark T L, Buck J A, Dilonardo J D, Coffey R M, Chalk M. Medicaid expenditures on behavioral health care. Psychiatric Services. 2003a;54(2):188–194. [PubMed: 12556599]
  498. Mark, T.L., Dilonardo, J.D., Chalk, M., and Coffey, R.M. Substance Abuse Detoxification: Improvements Needed in Linkage to Treatment. DHHS Pub. No. (SMA) 02-3728. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2002.
  499. Mark T L, Dilonardo J D, Chalk M, Coffey R M. Factors associated with the receipt of treatment following detoxification. Journal of Substance Abuse Treatment. 2003b;24(4):299–304. [PubMed: 12867203]
  500. Markarian, M., and Franklin, J. Substance abuse in minority populations. In: Frances, R.J., and Miller, S.I., eds. Clinical Textbook of Addictive Disorders. 2d ed. New York: Guilford Press, 1998. pp. 397–412.
  501. Markowitz J S, Myrick H, Hiott W. Clonidine dependence. Journal of Clinical Psychopharmacology. 1997;17(2):137–138. [PubMed: 10950490]
  502. Marlatt G A, Blume A W, Parks G A. Integrating harm reduction therapy and traditional substance abuse treatment. Journal of Psychoactive Drugs. 2001;33(1):13–21. [PubMed: 11332996]
  503. Marlatt, G.A., and Gordon, J. Determinants of relapse: Implications for the maintenance of behavior change. In: Davidson, P., and Davidson, S., eds. Behavioral Medicine: Changing Health Lifestyles. New York: Brunner/Mazel, pp. 410–452, 1980.
  504. Marlatt, G.A., Tucker, J.A., Donovan, D.M., and Vuchinich, R.E. Help-seeking by substance abusers: The role of harm reduction and behavioral-economic approaches to facilitate treatment entry and retention. In: Onken, L.S., Blaine, J.D., and Boren, J.J., eds. Beyond the Therapeutic Alliance: Keeping the Drug Dependent Individual in Treatment. NIDA Research Monograph 165. NIH Publication No. 97-4142. Rockville, MD: National Institute on Drug Abuse, 1997, pp. 44–84.
  505. Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence: Intake data from the National Treatment Outcome Research Study. British Journal of Psychiatry. 2000;176(March):285–289. [PubMed: 10755078]
  506. Marsella A J. Thoughts on cross-cultural studies on the epidemiology of depression. Culture, Medicine and Psychiatry. 1978;2(4):343–357.
  507. Martin A C, Schaffer S D, Campbell R. Managing alcohol-related problems in the primary care setting. Nurse Practitioner. 1999;24(8):14–18. [PubMed: 10479108]
  508. Mattick, R.P., Bell, J., and Daws, L.C. Review of the Evidence on the Effectiveness of Antagonists in Managing Opioid Dependence. National Drug and Research Centre, University of New South Wales, Australia, 1998.
  509. Mattick R P, Hall W. Are detoxification programmes effective? Lancet. 1996;347(8994):97–100. [PubMed: 8538351]
  510. Mayo-Smith M F. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. Journal of the American Medical Association. 1997;278(2):144–151. [PubMed: 9214531]
  511. Mayo-Smith M F, Bernard D. Late-onset seizures in alcohol withdrawal. Alcoholism: Clinical and Experimental Research. 1995;19(3):656–659.
  512. McCarty D, Caspi Y, Panas L, Krakow M, Mulligan D H. Detoxification centers: Who's in the revolving door? Journal of Behavioral Health Services and Research. 2000;27(3):245–257. [PubMed: 10932439]
  513. McCorry F, Garnick D W, Bartlett J, Cotter F, Chalk M. Developing performance measures for alcohol and other drug services in managed care plans. Washington Circle Group. Joint Commission Journal on Quality Improvement. 2000a;26(11):633–643. [PubMed: 11098426]
  514. McCorry, F., Garnick, D.W., Bartlett, J., Cotter, F., and Chalk, M. Improving Performance Measurement for Alcohol and Other Drug Services. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000b. http://www.samhsa.gov/mc/content/Quality%20Improvement%20and%20Performance%20Measures/perfmeas.html[Accessed August 31, 2001].
  515. McCrady, B.S., and Delaney, S.I. Self-help groups. In: Hester, R.K., and Miller, W.R., eds. Handbook of Alcoholism Treatment Approaches. 2d ed. Boston: Allyn and Bacon, 1995. pp. 160–175.
  516. McCrady B S, Epstein E E, Hirsch L S. Issues in the implementation of a randomized clinical trial that includes Alcoholics Anonymous: Studying AA-related behaviors during treatment. Journal of Studies on Alcohol. 1996;57:604–612. [PubMed: 8913991]
  517. McDonald, J.D., Morton, R., and Stewart, C. Clinical concerns with American Indian patients. In: VandeCreek, L., and Knapp, S., eds. Innovations in Clinical Practice: A Source Book. Sarasota, FL: Professional Resource Press/Professional Resource Exchange, 1993. pp. 437–454.
  518. McElhatton, P.R. Heart and circulatory system drugs. In: Schaefer, C.H., ed. Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment: With Updated Information on Recreational Drugs. Amsterdam: Elsevier, 2001. pp. 116–131.
  519. McElhatton P R, Bateman D N, Evans C, Pughe K R, Thomas S H. Congenital anomalies after prenatal ecstasy exposure. Lancet. 1999;354(9188):1441–1442. [PubMed: 10543673]
  520. McGee M D, Mee-Lee D. Rethinking patient placement: The human service matrix model for matching services to needs. Journal of Substance Abuse Treatment. 1997;14(2):141–148. [PubMed: 9258858]
  521. McGinnis J M, Foege W H. Actual causes of death in the United States. Journal of the American Medical Association. 1993;270(18):2207–2212. [PubMed: 8411605]
  522. McLaughlin L A, Braun K L. Asian and Pacific Islander cultural values: Considerations for health care decision making. Health and Social Work. 1998;23(2):116–126. [PubMed: 9598394]
  523. McLellan A T, Alterman A I, Metzger D S, Grissom G R, Woody G E, Luborsky L, O'Brien C P. Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: Role of treatment services. Journal of Consulting and Clinical Psychology. 1994;62(6):1141–1158. [PubMed: 7860812]
  524. McLellan A T, Grissom G R, Brill P, Durell J, Metzger D S, O'Brien C P. Private substance abuse treatments: Are some programs more effective than others? Journal of Substance Abuse Treatment. 1993;10(3):243–254. [PubMed: 8391086]
  525. McLellan A T, Hagan T A, Levine M, Gould F, Meyers K, Bencivengo M, Durell J. Supplemental social services improve outcomes in public addiction treatment. Addiction. 1998;93(10):1489–1499. [PubMed: 9926553]
  526. McLellan A T, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettnati H, Argeriou M. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment. 1992;9(3):199–213. [PubMed: 1334156]
  527. McLellan, A.T., Lewis, D., O'Brien, C.P., Hoffmann, N.G., and Kleber, H.D. Is Drug Dependence a Chronic Medical Illness: Implications for Treatment, Insurance and Outcome Evaluation. Philadelphia: Treatment Research Institute, 2002. http://www.bsa.ca.gov/lhcdir/drug/McClellanApr25.pdf[Accessed July 15, 2002].
  528. McLellan A T, Lewis D C, O'Brien C P, Kleber H D. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association. 2000;284(13):1689–1695. [PubMed: 11015800]
  529. McLellan A T, Luborsky L, Cacciola J, Griffith J, Evans F, Barr H L, O'Brien C P. New data from the Addiction Severity Index: Reliability and validity in three centers. Journal of Nervous and Mental Disease. 1985;173(7):412–423. [PubMed: 4009158]
  530. McLellan A T, Luborsky L, Woody G E, O'Brien C P. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168(1):26–33. [PubMed: 7351540]
  531. McLellan, A.T., and McKay, J.R. Components of successful treatment programs: Lessons from the research literature. In: Graham, A.W., Schultz, T.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998. pp. 327–343.
  532. McNiel, J., Sheffield, J.V.L., and Bartlett, J.G. Core elements of HIV primary care. In: Bartlett, J.G., Cheever, L.W., Johnson, M.P., and Paauw, D.S. A Guide to Primary Care of People with HIV/AIDS. Rockville, MD: Health Resources and Services Administration, 2004. http://hab.hrsa.gov/tools/primarycareguide/[Accessed February 9, 2006].
  533. Merikangas, K.R., Angst, J., Eaton, W., Canino, G., Rubio-Stipec, M., Wacker, H., Wittchen, H.U., Andrade, L., Essau, C., Whitaker, A., Kraemer, H., Robins, L.N., and Kupfer, D.J. Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: Results of an international task force. The British Journal of Psychiatry (Supplement) (30):58–67, 1996.
  534. Merrick E L, Garnick D W, Horgan C M, Goldin D, Hodgkin D, Sciegaj M. Benefits in behavioral health carve-out plans of Fortune 500 firms. Psychiatric Services. 2001;52(7):943–948. [PubMed: 11433112]
  535. Meyers R J, Miller W R, Hill D E, Tonigan J S. Community reinforcement and family training (CRAFT): Engaging unmotivated drug users in treatment. Journal of Substance Abuse. 1998;10(3):291–308. [PubMed: 10689661]
  536. Miles D R, Svikis D S, Kulstad J L, Haug N A. Psychopathology in pregnant drug-dependent women with and without comorbid alcohol dependence. Alcoholism: Clinical and Experimental Research. 2001;25(7):1012–1017.
  537. Miller, N.S. Psychiatric consequences of alcohol and drugs of abuse and addiction. In: Miller, N.S., ed. Pharmacology of Alcohol and Drugs of Abuse and Addiction. New York: Springer-Verlag, 1991. pp. 77–87.
  538. Miller N S. Comorbidity of psychiatric and alcohol/drug disorders: Interactions and independent status. Journal of Addictive Diseases. 1993;12(3):5–16. [PubMed: 8251545]
  539. Miller N S, Belkin B M, Gold M S. Multiple addictions: Co-synchronous use of alcohol and drugs. New York State Journal of Medicine. 1990a;90(12):596–600. [PubMed: 2277677]
  540. Miller N S, Chappel J N. History of the disease concept. Psychiatric Annals. 1991;21(4):196–205.
  541. Miller N S, Flaherty J A. Effectiveness of coerced addiction treatment (alternative consequences): A review of the clinical research. Journal of Substance Abuse Treatment. 2000;18(1):9–16. [PubMed: 10636601]
  542. Miller N S, Gold M S. Organic solvents and aerosols: An overview of abuse and dependence. Annals of Clinical Psychiatry. 1990;2:85–92.
  543. Miller N S, Gold M S. Abuse, addiction, tolerance, and dependence to benzodiazepines in medical and nonmedical populations. American Journal of Alcohol Abuse. 1991a;17(1):27–37.
  544. Miller N S, Gold M S. Dual diagnoses: Psychiatric syndromes in alcoholism and drug addiction. American Family Physician. 1991b;43(6):2071–2076. [PubMed: 2042549]
  545. Miller N S, Gold M S. The psychiatrist's role in integrating pharmacological and nonpharmacological treatments for addictive disorders. Psychiatric Annals. 1992;22(8):436–440.
  546. Miller N S, Gold M S. Dissociation of “conscious desire” (craving) from and relapse in alcohol and cocaine dependence. Annals of Clinical Psychiatry. 1994;6(2):99–106. [PubMed: 7804394]
  547. Miller N S, Gold M S. Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence. American Family Physician. 1998;58(1):139–146. [PubMed: 9672434]
  548. Miller N S, Mahler J C, Belkin B M, Gold M S. Psychiatric diagnosis in alcohol and drug dependence. Annals of Clinical Psychiatry. 1991a;3:79–89.
  549. Miller N S, Mahler J C, Gold M S. Suicide risk associated with drug and alcohol dependence. Journal of Addictive Diseases. 1991b;10(3):49–61. [PubMed: 1932152]
  550. Miller N S, Owley T, Eriksen A. Working with drug/alcohol-addicted patients in crisis. Psychiatric Annals. 1994;24(11):592–597.
  551. Miller, S.I., Frances, R.J., and Holmes, D.J. Psychotropic medications. In: Miller, W.R., ed. Alcoholism Treatment Approaches. New York: Pergamon Press, 1990b. pp. 231–241.
  552. Miller, W.R., Brown, J.M., Simpson, T.L., Handmaker, N.S., Bien, T.H., Luckie, L.F., Montgomery, H.A., Hester, R.K., and Tonigan, J.S. What works? A methodological analysis of the alcohol treatment outcome literature. In: Hester, R.K., and Miller, W.R., eds. Handbook of Alcoholism Treatment Approaches: Effective Alternatives. 2d ed. Boston: Allyn and Bacon, 1995. pp. 12–44.
  553. Miller W R, Meyers R J, Tonigan J S. Engaging the unmotivated in treatment for alcohol problems: A comparison of three strategies for intervention through family members. Journal of Consulting and Clinical Psychology. 1999;67(5):688–697. [PubMed: 10535235]
  554. Miller, W.R., and Rollnick, S. Motivational Interviewing: Preparing People for Change. 2d ed. New York: Guilford Press, 2002.
  555. Miller, W.R., and Rollnick, S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press, 1991.
  556. Miller, W.R., and Sanchez, V.C. Motivating young adults for treatment and lifestyle change. In: Howard, G.S., and Nathan, P.E., eds. Alcohol Use and Misuse by Young Adults. Notre Dame, IN: Notre Dame University Press, 1994. pp. 55–81.
  557. Minnis J R. Toward an understanding of alcohol abuse among the elderly: A sociological perspective. Journal of Alcohol and Drug Education. 1988;33(3):32–40.
  558. Miotto, K., Roth, B., and Texas Commission on Alcohol and Drug Abuse. GHB Withdrawal Syndrome. Austin, TX: Texas Commission on Alcohol and Drug Abuse, 2001. http://www.tcada.state.tx.us/research/populations/GHB_Withdrawal.pdf[Accessed February 25, 2005].
  559. Mitchell, E.R. Fighting Drug Abuse With Acupuncture: Treatment That Works. Berkeley, CA: Pacific View Press, 1995.
  560. Mizes J S, Sloan D M, Pingitore R, Seagraves K, Spring B, Kristellar J. The influence of weight-related variables on smoking cessation. Behavior Therapy. 1998;29:371–385.
  561. Moak D H, Anton R F. Alcohol-related seizures and the kindling effect of repeated detoxifications: The influence of cocaine. Alcohol and Alcoholism. 1996;31(2):135–143. [PubMed: 8737008]
  562. Modesto-Lowe V, Kranzler H R. Diagnosis and treatment of alcohol-dependent patients with comorbid psychiatric disorders. Alcohol Research and Health. 1999;23(2):144–149. [PubMed: 10890809]
  563. Moffic H S, Kinzie J D. The history and future of cross-cultural psychiatric services. Community Mental Health Journal. 1996;32(6):581–592. [PubMed: 8905230]
  564. Moggi F, Ouimette P C, Finney J W, Moos R H. Effectiveness of treatment for substance abuse and dependence for dual diagnosis patients: A model of treatment factors associated with one-year outcomes. Journal of Studies on Alcohol. 1999;60(6):856–866. [PubMed: 10606499]
  565. Mojtabai R, Zivin J G. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: A propensity score analysis. Health Services Research. 2003;38(1):233–259. [PMC free article: PMC1360883] [PubMed: 12650390]
  566. Moller H J. Effectiveness and safety of benzodiazepines. Journal of Clinical Psychopharmacology. 1999;19(6):2S–11S. [PubMed: 10587278]
  567. Morey L. Patient placement criteria: Linking typologies to managed care. Alcohol Health and Research World. 1996;20(1):36–44.
  568. Moss A R, Hahn J A, Tulsky J P, Daley C L, Small P M, Hopewell P C. Tuberculosis in the homeless. A prospective study. American Journal of Respiratory and Critical Care Medicine. 2000;162(2 Pt 1):460–464. [PubMed: 10934071]
  569. Motet-Grigoras C N, Schuckit M A. Depression and substance abuse in handicapped young men. Journal of Clinical Psychiatry. 1986;47(5):234–237. [PubMed: 2939063]
  570. Moylan P L, Jones H E, Haug N A, Kissin W B, Svikis D S. Clinical and psychosocial characteristics of substance-dependent pregnant women with and without PTSD. Addictive Behaviors. 2001;26:469–474. [PubMed: 11436939]
  571. Mulvaney F D, Alterman A I, Boardman C R, Kampman K. Cocaine abstinence symptomatology and treatment attrition. Journal of Substance Abuse Treatment. 1999;16(2):129–135. [PubMed: 10023610]
  572. Mumola, C.J. Substance Abuse and Treatment, State and Federal Prisoners, 1997. Bureau of Justice Statistics Special Report. NCJ 172871. Washington, DC: Bureau of Justice Statistics, 1999. http://www.ojp.usdoj.gov/bjs/abstract/satsfp97.htm[Accessed July 21, 2003].
  573. Najavits L M, Gastfriend D R, Barber J P, Reif S, Muenz L R, Blaine J, Frank A, Crits-Christoph P, Thase M, Weiss R D. Cocaine dependence with and without PTSD among subjects in the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. American Journal of Psychiatry. 1998;155(2):214–219. [PubMed: 9464200]
  574. National Center on Addiction and Substance Abuse. Shoveling Up: The Impact of Substance Abuse on State Budgets. New York: National Center on Addiction and Substance Abuse, 2001.
  575. National Conference of Commissioners on Uniform State Laws. Uniform Alcoholism and Intoxication Treatment Act. Vail, CO: Commissioners on Uniform State Laws, 1971. http://www.law.upenn.edu/bll/ulc/fnact99/1970s/uaita71.pdf[Accessed January 14, 2004].
  576. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide. NIH Publication No. 00-4180. Bethesda, MD: National Institutes of Health, 1999. http://165.112.78.61/PODAT/PODATindex.html[Accessed March 23, 2003].
  577. National Institute on Drug Abuse. Facts about drug abuse and hepatitis c. NIDA Notes 15(1):1–3. Rockville, MD: National Institute on Drug Abuse, 2000. http://www.nida.nih.gov/NIDA_Notes/NNVol15N1/tearoff.html[Accessed February 8, 2006].
  578. National Institute on Drug Abuse. Inhalant Abuse. NIH Publication No. 05-3818. Bethesda, MD: National Institutes of Health, 2005. http://www.nida.nih.gov/PDF/RRInhalants.pdf[Accessed January 18, 2006].
  579. National Institutes of Health. Acupuncture. NIH Consensus Statement 1997 Nov 3–5. Bethesda, MD: National Institutes of Health, 1997. http://consensus.nih.gov/cons/107/107_statement.pdf[Accessed March 31, 2003].
  580. Nazrul Islam S K, Jahangir Hossain K, Ahmed A, Ahsan M. Nutritional status of drug addicts undergoing detoxification: Prevalence of malnutrition and influence of illicit drugs and lifestyle. British Journal of Nutrition. 2004;88(5):507–513. [PubMed: 12425731]
  581. Nazrul Islam S K, Jahangir Hossain K, Ahsan M. Serum vitamin E, C and A status of the drug addicts undergoing detoxification: Influence of drug habit, sexual practice and lifestyle factors. European Journal of Clinical Nutrition. 2001;55(11):1022–1027. [PubMed: 11641753]
  582. Nebelkopf E. Holistic program for the drug addict and alcoholic. Journal of Psychoactive Drugs. 1981;13(4):345–351. [PubMed: 7040618]
  583. Nebelkopf E. Herbal therapy in the treatment of drug use. International Journal of the Addictions. 1987;22(8):695–717. [PubMed: 3316062]
  584. Nebelkopf E. Herbs and substance abuse treatment: A 10-year perspective. Journal of Psychoactive Drugs. 1988;20(3):349–354. [PubMed: 3069989]
  585. Nelipovich M, Buss E. Alcohol abuse and persons who are blind: Treatment considerations. Alcohol Health and Research World. 1989;13(2):129–131.
  586. Neu, H.C. Pneumonia. In: Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby, pp. 1868–1876. 1994.
  587. Newman, C.F. Establishing and maintaining a therapeutic alliance with substance abuse patients: A cognitive therapy approach. In: Onken, L.S., Blaine, J., and Boren, J.D., eds. Beyond the Therapeutic Alliance: Keeping the Drug-Dependent Individual in Treatment. NIDA Research Monograph 165. NIH Publication No. 97-4142. Rockville, MD: National Institute on Drug Abuse, 1997. pp. 181–206.
  588. News and Notes. Study finds widespread implementation of managed behavioral health care programs in the public sector. Psychiatric Services 50(2):278, 1999.
  589. Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein M G, Keuthen N, DePue J, Kristeller J, Ockene J, Prochazka A, Chiles J A, Abrams D B. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. Journal of Consulting and Clinical Psychology. 2002;70(4):887–896. [PMC free article: PMC1852538] [PubMed: 12182272]
  590. Nordahl T E, Salo R, Natsuaki Y, Galloway G P, Waters C, Moore C D, Kile S, Buonocore M H. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Archives of General Psychiatry. 2005;62(4):444–452. [PubMed: 15809412]
  591. NIH Panel Issues Consensus Statement on Acupuncture. NIH News Release. Bethesda, MD: National Institutes of Health, 1997. http://www.nih.gov/news/pr/nov97/od-05.htm[Accessed March 31, 2003].
  592. Nutt D, Adinoff B, Linnoila M. Benzodiazepines in the treatment of alcoholism. Recent Developments in Alcoholism. 1989;7:283–313. [PubMed: 2564689]
  593. O'Connor P G, Kosten T R. Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association. 1998;279(3):229–234. [PubMed: 9438745]
  594. Office of Applied Studies. Summary of Findings from the 2000 National Household Survey on Drug Abuse. DHHS Publication No. (SMA) 01-3549. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2001. http://www.samhsa.gov/oas/NHSDA/2kNHSDA.pdf[Accessed July 16, 2002].
  595. Office of Applied Studies. Results from the 2001 National Household Survey on Drug Abuse: Vol.1. Summary of National Findings. National Household Survey on Drug Abuse Series: H-17. DHHS Publication No. (SMA) 02-3758. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2002a.
  596. Office of Applied Studies. National Survey of Substance Abuse Treatment Services (N-SSATS): 2000. Data on Substance Abuse Treatment Facilities. DASIS Series: S-16. DHHS Publication No. (SMA) 02-3668. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2002b. http://wwwdasis.samhsa.gov/00nssats/nssats2000report.pdf[Accessed January 10, 2003].
  597. Office of Applied Studies. Treatment Episode Data Set (TEDS): 1992-2000. National Admissions to Substance Abuse Treatment Services. Drug and Alcohol Services Information System Series: S-17. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2002c. http://wwwdasis.samhsa.gov/teds00/teds_rpt_2000_web.pdf[Accessed May 28, 2003].
  598. Office of Applied Studies. The National Survey of Substance Abuse Treatment Services (N-SSATS). The DASIS Report. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2003a. http://www.samhsa.gov/OAS/2k3/NSSATS/NSSATS.pdf[Accessed December 16, 2003].
  599. Office of Applied Studies. Overview of Findings from the 2002 National Survey on Drug Use and Health. NHSDA Series H-21. DHHS Publication No. (SMA) 03-3774. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2003b. http://www.samhsa.gov/oas/NHSDA/2k2NSDUH/2k2SoFOverviewW.pdf[Accessed February 11, 2004].
  600. Office of Applied Studies. Treatment Episode Data Set (TEDS): 1992-2001. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-20 DHHS Publication No. (SMA) 03-3778 Rockville, MD: Substance Abuse and Mental Health Services Administration 2003c. http://wwwdasis.samhsa.gov/teds01/TEDS2K1Index.htm[Accessed February 11, 2004].
  601. Office of Applied Studies. Treatment Episode Data Set (TEDS): 1992-2002. Chapter 3—Characteristics of Admissions: 2002. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-23 DHHS Publication No. (SMA) 04-3965 Rockville, MD: Substance Abuse and Mental Health Services Administration 2004. http://wwwdasis.samhsa.gov/teds02/TEDS2K2Chp3.htm[Accessed July 5, 2005].
  602. Office of Applied Studies. Overview of Findings from the 2004 National Survey on Drug Use and Health. DHHS Publication No. (SMA) 05-4061. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005a. http://oas.samhsa.gov/NSDUH/2k4NSDUH/2k4Overview/2k4Overview.pdf[Accessed September 9, 2005].
  603. Office of Applied Studies. Polydrug Admissions: 2002. The DASIS Report. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005b. http://oas.samhsa.gov/2k5/polydrugTX/polydrugTX.htm[Accessed February 9, 2006].
  604. Office of Applied Studies. Results from the 2004 National Survey on Drug Use and Health: National Findings. DHHS Publication No. (SMA) 05-4062. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005c. http://oas.samhsa.gov/NSDUH/2k4nsduh/2k4Results/2k4Results.pdf[Accessed September 8, 2005].
  605. Office of Applied Studies. Treatment Episode Data Set (TEDS): 1993-2003. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-29 DHHS Publication No. (SMA) 05-4118 Rockville, MD: Substance Abuse and Mental Health Services Administration 2005d. http://wwwdasis.samhsa.gov/teds03/teds_2003_rpt.pdf[Accessed February 16, 2006].
  606. Office of the Inspector General. Follow-up to Detoxification Services for Medicaid Beneficiaries. OEI-07-97-00270. Washington, DC: Department of Health and Human Services, Office of Inspector General, 1998. http://oig.hhs.gov/oei/reports/oei-07-97-00270.pdf[Accessed March 4, 2004].
  607. Office of National Drug Control Policy. National Drug Control Strategy. Washington, DC: Office of National Drug Control Policy, 1998.
  608. Office of National Drug Control Policy. National Drug Control Strategy. NCJ 192260. Washington, DC: Office of National Drug Control Policy, 2002. http://www.whitehousedrugpolicy.gov/publications/pdf/Strategy2002.pdf[Accessed February 13, 2002].
  609. Okuyemi K S, Ahluwalia J S, Harris K J. Pharmacotherapy of smoking cessation. Archives of Family Medicine. 2000;9(3):270–281. [PubMed: 10728115]
  610. Onken, L.S., Blaine, J., and Boren, J.D., eds. Beyond the Therapeutic Alliance: Keeping the Drug-Dependent Individual in Treatment. NIDA Research Monograph 165. NIH Publication No. 97-4142. Rockville, MD: National Institute on Drug Abuse, 1997.
  611. Oss, M.E., and Clary, J.H. Managed Behavioral Health Marketshare in the United States, 1998-1999. Gettysburg, PA: Open Minds, 1999.
  612. Parker J D. A brief telephone intervention targeting treatment engagement from a substance abuse program wait list. Journal of Behavior Health Services and Research. 2002;29(3):288–303.
  613. Parra, G. Welfare Reform and Substance Abuse: Innovative State Strategies. NHPF Issue Brief. Washington, DC: National Health Policy Forum, 2002. http://www.nhpf.org/pdfs/8%2D771%2B%28web%29%2Epdf[Accessed July 15, 2002].
  614. Parrott A C, Sisk E, Turner J J. Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug and Alcohol Dependence. 2000;60(1):105–110. [PubMed: 10821995]
  615. Pelican S, Batchelor B, Belshaw J, Osborn W, Pearce J, Przekurat C, Schumacher P, Strauss K. Nutrition services for alcohol/substance abuse clients. Indian Health Service's tribal survey provides insight. Journal of the American Dietetic Association. 1994;94(8):835–836. [PubMed: 8046172]
  616. Pena J M, Bland I J, Shervington D, Rice J C, Foulks E F. Racial identity and its assessment in a sample of African-American men in treatment for cocaine dependence. American Journal of Drug and Alcohol Abuse. 2000;26(1):97–112. [PubMed: 10718166]
  617. Penick E C, Powell B J, Nickel E J, Bingham S F, Riesenmy K R, Read M R, Campbell J. Comorbidity of lifetime psychiatric disorder among male alcoholic patients. Alcoholism: Clinical and Experimental Research. 1994;18(6):1289–1293.
  618. Perez-Stable E J, Herrera B, Jacob P, Benowitz N L. Nicotine metabolism and intake in black and white smokers. Journal of the American Medical Association. 1998;280(2):152–156. [PubMed: 9669788]
  619. Perine J L, Schare M L. Effect of counselor and client education in nicotine addiction on smoking in substance abusers. Addictive Behaviors. 1999;24(3):443–447. [PubMed: 10400284]
  620. Perkins K A. Smoking cessation in women. Special considerations. CNS Drugs. 2001;15(5):391–411. [PubMed: 11475944]
  621. Perkins K A, Marcus M D, Levine M D, D'Amico D, Miller A, Broge M, Ashcom J, Shiffman S. Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. Journal of Consulting and Clinical Psychology. 2001;69(4):604–613. [PubMed: 11550727]
  622. Perrin, E.B., and Koshel, J.J., eds. Assessment of Performance Measures for Public Health, Substance Abuse, and Mental Health. Washington, DC: National Academy Press, 1997.
  623. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clinical Pharmacokinetics. 1982;7(4):336–352. [PubMed: 6749369]
  624. Peters R G, May R L, Kearns W D. Drug treatment in jails: Results of a nationwide survey. Journal of Criminal Justice. 1992;20(4):283–295.
  625. Pfab R, Hirtl C, Zilker T. Opiate detoxification under anesthesia: No apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. Journal of Toxicology. Clinical Toxicology. 1999;37(1):43–50. [PubMed: 10078159]
  626. Physicians' Desk Reference. 58th ed. Oradell, NJ: Medical Economics, 2004.
  627. Pi, E.H., and Gray, G.E. A cross-cultural perspective on psychopharmacology. In: The Hatherleigh Guide to Psychopharmacology. New York: Hatherleigh Press, 1999. pp. 327–358.
  628. Pires, S., Stroul, B., and Armstrong, M. Health Care Reform Tracking Project: Tracking State Managed Care Reforms as They Affect Children and Adolescents with Behavioral Health Disorders and Their Families - 1999 Impact Analysis. Tampa, FL: Louis de la Parte Florida Mental Health Institute, 2000. http://www.fmhi.usf.edu/institute/pubs/pdf/cfs/rtc/healthcaretracking/99ImpactAnalysisExecSumSA.pdf[Accessed July 15, 2002].
  629. Pitts W R, Lange R A, Cigarroa J E, Hillis L D. Cocaine-induced myocardial ischemia and infarction: Pathophysiology, recognition, and management. Progress in Cardiovascular Diseases. 1999;40(1):65–76. [PubMed: 9247556]
  630. Pokorny A D, Miller B A, Kaplan H B. The brief MAST: A shortened version of the Michigan Alcoholism Screening Test. American Journal of Psychiatry. 1972;129(3):342–345. [PubMed: 5053717]
  631. Polednak A P. Recent trends in incidence rates for selected alcohol-related cancers in the United States. Alcohol and Alcoholism. 2005;40(3):234–238. [PubMed: 15797879]
  632. Pond S M, Kreek M J, Tong T G, Raghunath J, Benowitz N L. Altered methadone pharmacokinetics in methadone-maintained pregnant women. Journal of Pharmacology and Experimental Therapeutics. 1985;233(1):1–6. [PubMed: 3981450]
  633. Pope H G, Katz D L, Hudson J I. Anorexia nervosa and “reverse anorexia” among 108 male bodybuilders. Comprehensive Psychiatry. 1993;34(6):406–409. [PubMed: 8131385]
  634. Post R M, Uhde T W, Roy-Byrne P P, Joffe R T. Correlates of antimanic response to carbamazepine. Psychiatry Research. 1987;21(1):71–83. [PubMed: 2885878]
  635. Potter J F, James O F. Clinical features and prognosis of alcoholic liver disease in respect of advancing age. Gerontology. 1987;33(6):380–387. [PubMed: 3443312]
  636. Prater C D, Miller K E, Zylstra R G. Outpatient detoxification of the addicted or alcoholic patient. American Family Physician. 1999;60(4):1175–1183. [PubMed: 10507746]
  637. Project MATCH Research Group. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. Journal of Studies on Alcohol. 1997;58(1):7–29. [PubMed: 8979210]
  638. Rathlev N K, D'Onofrio G, Fish S S, Harrison P M, Bernstein E, Hossack R W, Pickens L. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Annals of Emergency Medicine. 1994;23(3):513–518. [PubMed: 8135426]
  639. Rawson, R., McCann, M., Huber, A., and Shoptaw, S. Contingency management and relapse prevention as stimulant abuse treatment interventions. In: Higgins, S.T., ed. Motivating Behavior Change Among Illicit-Drug Abusers: Research on Contingency Management Interventions. Washington, DC: American Psychological Association, 1999. pp. 57–74.
  640. Reilly, P.M., and Shopshire, M.S. Anger Management for Substance Abuse and Mental Health Clients: A Cognitive Behavioral Therapy Manual. DHHS Publication No. (SMA) 02-3756. Rockville, MD: Center for Substance Abuse Treatment, 2002.
  641. Remler D K, Gray B M, Newhouse J P. Does managed care mean more hassle for physicians? Inquiry. 2000;37(3):304–316. [PubMed: 11111287]
  642. Reoux J P, Saxon A J, Malte C A, Baer J, Sloan K. Divalproex Sodium in alcohol withdrawal: A randomized double-blind placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research. 2001;25(9):1324–1329.
  643. Resnick R B, Kestenbaum R S, Washton A, Poole D. Naloxone-precipitated withdrawal: A method for rapid induction onto naltrexone. Clinical Pharmacology and Therapeutics. 1977;21(4):409–413. [PubMed: 849672]
  644. Rhem, K.T. Drug, Alcohol Treatment Available to DoD Beneficiaries. American Forces Information Service News Articles. Washington, DC: U.S. Department of Defense, 2001. http://www.defenselink.mil/news/Oct2001/n10112001_200110114.html[Accessed May 21, 2002].
  645. Rickels K, Demartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. Journal of Clinical Psychopharmacology. 1999;19(6 Suppl 2):12S–16S. [PubMed: 10587279]
  646. Rickels K, Schweizer E, Case W G, Greenblatt D J. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Archives of General Psychiatry. 1990;47(10):899–907. [PubMed: 2222129]
  647. Riordan C E, Kleber H D. Rapid opiate detoxification with clonidine and naloxone. Lancet. 1980;1(8177):1079–1080. [PubMed: 6103408]
  648. Ro M. Moving forward: Addressing the health of Asian American and Pacific Islander women. American Journal of Public Health. 2002;92(4):516–519. [PMC free article: PMC1447107] [PubMed: 11919042]
  649. Robert, E., Reuvers, M., and Shaefer, C. Antiepileptics. In: Schaefer, C.H., ed. Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment: With Updated Information on Recreational Drugs. Amsterdam: Elsevier, 2001. pp. 46–57.
  650. Robert Wood Johnson Foundation. Substance Abuse: The Nation's Number One Health Problem. Key Indicators for Policy. Princeton, NJ: The Robert Wood Johnson Foundation, 2001.
  651. Robins, L.N., and Regier, D.A., eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: Free Press, 1991.
  652. Rodgers J. Cognitive performance amongst recreational users of “ecstasy” Psychopharmacology. 2000;151(1):19–24. [PubMed: 10958112]
  653. Rodgers J H, Barnett P G. Two separate tracks? A national multivariate analysis of differences between public and private substance abuse treatment programs. American Journal of Drug and Alcohol Abuse. 2000;26(3):429–442. [PubMed: 10976667]
  654. Roman, P.M., Blum, T.C., and Johnson, A. National Treatment Center Study: Six and Twelve Month Follow-up Summary Report. Athens, GA: University of Georgia, Institute for Behavioral Research, 1997. http://www.uga.edu/ntcs/Newsletter.htm[Accessed October 30, 2002].
  655. Ron M A. Volatile substance abuse: A review of possible long-term neurological, intellectual and psychiatric sequelae. British Journal of Psychiatry. 1986;148:235–246. [PubMed: 3013354]
  656. Rosenbaum, S., Teitelbaum, J., and Mauery, D.R. An Analysis of the Medicaid IMD Exclusion. Washington, DC: GWU School of Public Health and Health Services, 2002. http://www.gwhealthpolicy.org/downloads/behavioral_health/reports/IMD%20Report%201202.pdf[Accessed January 5, 2005].
  657. Rosenberg M H, Deerfield L J, Baruch E M. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: Recommendations for management. American Journal of Drug and Alcohol Abuse. 2003;29(2):487–496. [PubMed: 12765217]
  658. Rosin A J, Glatt M M. Alcohol excess in the elderly. Quarterly Journal of Studies on Alcohol. 1971;32(1):53–59. [PubMed: 5546053]
  659. Rouse, B.A., Carter, J.H., and Rodriguez-Andrew, S. Race/ethnicity and other sociocultural influences on alcoholism treatment for women. In: Galanter, M., ed. Recent Developments in Alcoholism, Vol. 12: Alcoholism and Women. New York: Plenum Press, 1995. pp. 343–367.
  660. Royer C M, Dickson-Fuhrmann E, McDermott C H, Taylor S, Rosansky J S, Jarvik L F. Portraits of change: Case studies from an elder-specific addiction program. Journal of Geriatric Psychiatry and Neurology. 2000;13(3):130–133. [PubMed: 11001135]
  661. Rubin, A., and Gastfriend, D.R. Patient placement criteria and their relation to access to appropriate level of care and engagement in alcoholism treatment. Recent Developments in Alcoholism 15:157–76:157–176, 2001.
  662. Rubinstein, G. The State of State Policy on TANF & Addiction: Findings from the Survey of State Policies and Practices to Address Alcohol and Drug Problems Among TANF. Washington, DC: The Legal Action Center, 2002. http://www.lac.org/pubs/gratis/state_of_state.pdf[Accessed March 4, 2004].
  663. Russell M, Martier S S, Sokol R J, Mudar P, Bottoms S, Jacobson S, Jacobson J. Screening for pregnancy risk-drinking. Alcoholism, Clinical and Experimental Research. 1994;18(5):1156–1161.
  664. Rychtarik R G, Connors G J, Whitney R B, McGillicuddy N B, Fitterling J M, Wirtz P W. Treatment settings for persons with alcoholism: Evidence for matching clients to inpatient versus outpatient care. Journal of Consulting and Clinical Psychology. 2000;68(2):277–289. [PubMed: 10780128]
  665. Sadd, S., and Young, D.W. Nonmedical treatment of indigent alcoholics: A review of recent research findings. Alcohol Health and Research World (Spring):48–53, 1987.
  666. Saitz R, Mayo-Smith M F, Roberts M S, Redmond H A, Bernard D R, Calkins D R. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. Journal of the American Medical Association. 1994;272(7):519–523. [PubMed: 8046805]
  667. Salloum, I.M., and Thase, M.E. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disorders 2(3 Pt. 2):269–280, 2000.
  668. Samet J H, Friedmann P D, Saitz R. Benefits of linking primary medical care and substance abuse services: Patient, provider, and societal perspectives. Archives of Internal Medicine. 2001;161(1):85–91. [PubMed: 11146702]
  669. Santolaria-Fernandez F J, Gomez-Sirvent J L, Gonzalez-Reimers C E, Batista-Lopez J N, Jorge-Hernandez J A, Rodriguez-Moreno F, Martinez-Riera A, Hernandez-Garcia M T. Nutritional assessment of drug addicts. Drug and Alcohol Dependence. 1995;38(1):11–18. [PubMed: 7648992]
  670. Saremi A, Hanson R L, Williams D E, Roumain J, Robin R W, Long J C, Goldman D, Knowler W C. Validity of the CAGE questionnaire in an American Indian population. Journal of Studies on Alcohol. 2001;62(3):294–300. [PubMed: 11414338]
  671. Satel S L, Price L H, Palumbo J M, McDougle C J, Krystal J H, Gawin F, Charney D S, Heninger G R, Kleber H D. Clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. American Journal of Psychiatry. 1991;148:1712–1716. [PubMed: 1957935]
  672. Saunders J B, Aasland O G, Babor T F, de la Fuente J R, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction. 1993;88(6):791–804. [PubMed: 8329970]
  673. Saunders, P.A. Epidemiology of alcohol problems and drinking patterns. In: John, R.M., Copeland, M.T., Aboou-Saleh, M.T., and Blazer, D.G., eds. Principles and Practice of Geriatric Psychiatry. New York: Wiley, 1994. pp. 801–805.
  674. Schaefer, C.H. Recreational drugs. In: Schaefer, C.H., ed. Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment: With Updated Information on Recreational Drugs. Amsterdam: Elsevier, 2001. pp. 214–224.
  675. Schatz, B., and O'Hanlan, K. Anti-Gay Discrimination in Medicine: Results of a National Survey of Lesbian, Gay and Bisexual Physicians. San Francisco: American Association of Physicians for Human Rights (AAPHR), 1994.
  676. Schneider U, Altmann A, Baumann M, Bernzen J, Bertz B, Bimber U, Broese T, Broocks A, Burtscheidt W, Cimander K F, Degkwitz P, Driessen M, Ehrenreich H, Fischbach E, Folkerts H, Frank H, Gurth D, Havemann-Reinecke U, Heber W, Heuer J, Hingsammer A, Jacobs S, Krampe H, Lange W, Lay T, Leimbach M, Lemke M R, Leweke M, Mangholz A, Massing W, Meyenberg R, Porzig J, Quattert T, Redner C, Ritzel G, Rollnik J D, Sauvageoll R, Schlafke D, Schmid G, Schroder H, Schwichtenberg U, Schwoon D, Seifert J, Sickelmann I, Sieveking C F, Spiess C, Stiegemann H H, Stracke R, Straetgen H D, Subkowski P, Thomasius R, Tretzel H, Verner L J, Vitens J, Wagner T, Weirich S, Weiss I, Wendorff T, Wetterling T, Wiese B, Wittfoot J. Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: The first multicentre study in Germany. Alcohol and Alcoholism. 2001;36(3):219–223. [PubMed: 11373258]
  677. Schoenbaum M, Zhang W, Sturm R. Costs and utilization of substance abuse care in a privately insured population under managed care. Psychiatric Services. 1998;49(12):1573–1578. [PubMed: 9856619]
  678. Schonfeld L, Dupree L W. Treatment approaches for older problem drinkers. International Journal of the Addictions. 1995;30(13–14):1819–1842. [PubMed: 8751320]
  679. Schuckit M A. Alcoholism and other psychiatric disorders. Hospital and Community Psychiatry. 1983;34(11):1022–1027. [PubMed: 6642446]
  680. Schuckit, M.A. Dual diagnosis: Psychiatric picture among substance abusers. In: Miller, N.S., ed. Principles of Addiction Medicine. 1st ed. Chevy Chase, MD: American Society of Addiction Medicine, 1994.
  681. Schuckit, M.A. Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment. 5th ed. New York: Kluwer Academic/Plenum Publishers, 2000.
  682. Schuckit M A, Monteiro M G. Alcoholism, anxiety and depression. British Journal of Addiction. 1988;83(12):1373–1380. [PubMed: 3233407]
  683. Schuh K J, Schuh L M, Henningfield J E, Stitzer M L. Nicotine nasal spray and vapor inhaler: Abuse liability assessment. Psychopharmacology. 1997;130(4):352–361. [PubMed: 9160851]
  684. Schuylze-Delrieu, K.S., and Summers, R.W. Esophageal diseases. In: Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby, 1994. pp. 390–402.
  685. Schweizer E, Rickels K, Case W G, Greenblatt D J. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Archives of General Psychiatry. 1990;47(10):908–915. [PubMed: 2222130]
  686. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Archives of General Psychiatry. 1993;50(1):51–60. [PubMed: 8422222]
  687. Scialli, A. Hormones. In: Schaefer, C.H., ed. Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment: With Updated Information on Recreational Drugs. Amsterdam: Elsevier, 2001. pp. 132–148.
  688. Scott R B. Alcohol effects in the elderly. Comprehensive Therapy. 1989;15(6):8–12. [PubMed: 2661128]
  689. Sees K L, Clark H W. When to begin smoking cessation in substance abusers. Journal of Substance Abuse Treatment. 1993;10(2):189–195. [PubMed: 8510193]
  690. Sees K L, Delucchi K L, Masson C, Rosen A, Clark H W. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence. Journal of the American Medical Association. 2000;283(10):1303–1310. [PubMed: 10714729]
  691. Self-reported frequent mental distress among adults—United States, 1993-1996. Morbidity and Mortality Weekly Report 47(16):326–331, 1998.
  692. Sellers, E.M., and Naranjo, C.A. Strategies for improving the treatment of alcohol withdrawal. In: Naranjo, C.A., and Sellers, E.M., eds. Research Advances in New Psychopharmacological Treatments for Alcoholism. New York: Elsevier Science Publishers, 1985. pp. 157–170.
  693. Semansky R M, Koyanagi C, Vandivort-Warren R. Behavioral health screening policies in Medicaid programs nationwide. Psychiatric Services. 2003;54(5):736–739. [PubMed: 12719507]
  694. Seoane A, Carrasco G, Cabre L, Puiggros A, Hernandez E, Alvarez M, Costa J, Molina R, Sobrepere G. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. British Journal of Psychiatry. 1997;171:340–345. [PubMed: 9373422]
  695. Seppa K, Sillanaukee P. Women, alcohol, and red cells. Alcoholism: Clinical and Experimental Research. 1994;18(5):1168–1171.
  696. Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. British Journal of Psychiatry. 1993;163:386–393. [PubMed: 8104653]
  697. Seymour, R.B., and Smith, D.E. Drugfree: A Unique, Positive Approach to Staying Off Alcohol and Other Drugs. New York: Facts on File Publications, 1987.
  698. Shaffer H J, Simoneau G. Reducing resistance and denial by exercising ambivalence during the treatment of addiction. Journal of Substance Abuse Treatment. 2001;20(1):99–105. [PubMed: 11239735]
  699. Shannon M, Quang L S. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: A case report and review of the literature. Pediatric Emergency Care. 2000;16(6):435–440. [PubMed: 11138892]
  700. Shaw G K. Detoxification: The use of benzodiazepines. Alcohol and Alcoholism. 1995;30(6):765–770. [PubMed: 8679017]
  701. Shaw G K, Waller S, Latham C J, Dunn G, Thomson A D. The detoxification experience of alcoholic in-patients and predictors of outcome. Alcohol and Alcoholism. 1998;33(3):291–303. [PubMed: 9632055]
  702. Shiffman S M. Relapse following smoking cessation: A situational analysis. Journal of Consulting and Clinical Psychology. 1982;50(1):71–86. [PubMed: 7056922]
  703. Shiffman S M, Paty J A, Rohay J M, Di Marino M E, Gitchell J. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine polacrilex gum therapy. Archives of Internal Medicine. 2000;160(11):1675–1681. [PubMed: 10847261]
  704. Shulman G D. Substance abuse treatment: The missing link. Managed care hates overtreatment and providers despise “undertreatment” Behavioral Health Management. 1998;18(4):34–36.
  705. Shwartz M, Sahz R, Mulvey R, Brannigan P. Value of acupuncture detoxification programs in a substance abuse treatment system. Journal of Substance Abuse Treatment. 1999;17(4):305–312. [PubMed: 10587932]
  706. Silagy, C., Mant, D., Fowler, G., and Lancaster, T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews (3):CD000146, 2000.
  707. Simko, M.D., Cowell, C., and Gilbride, J.A. Nutrition Assessment: A Comprehensive Guide for Planning Intervention. 2nd ed. Gaithersburg, MD: Aspen Publishers, 1995.
  708. Simpson D D, Joe G W, Rowan-Szal G A, Greener J M. Drug abuse treatment process components that improve retention. Journal of Substance Abuse Treatment. 1997;14(6):565–572. [PubMed: 9437628]
  709. Singer J, Lindamood K. Crisis of Access II: Fewer addiction services delivered through managed care; Medicaid managed care weakens public addiction treatment system. The Abell Report. 2000;13(5):1–12.
  710. Sivilotti M L, Burns M J, Aaron C K, Greenberg M J. Pentobarbital for severe gamma-butyrolactone withdrawal. Annals of Emergency Medicine. 2001;38(6):660–665. [PubMed: 11719746]
  711. Sladen B J, Mozdzierz G J. An MMPI scale to predict premature termination from inpatient alcohol treatment. Journal of Clinical Psychology. 1985;41(6):855–862. [PubMed: 4078014]
  712. Smart R G. Young alcoholics in treatment: Their characteristics and recovery rates at follow-up. Alcoholism: Clinical and Experimental Research. 1979;3(1):19–23.
  713. Smith, M., and Lin, K.M. A biological, environmental, and cultural basis for ethnic differences in treatment. In: Kato, P.M., and Mann, T., eds. Handbook of Diversity Issues in Health Psychology. New York: Plenum Press, 1996. pp. 389–406.
  714. Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez J R, Boada L D. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: A report of two cases and a review of the literature. British Journal of Sports Medicine. 2005;39(5):e27. [PMC free article: PMC1725213] [PubMed: 15849280]
  715. Sonne S C, Brady K T. Substance abuse and bipolar comorbidity. Psychiatric Clinics of North America. 1999;22(3):609–627. [PubMed: 10550858]
  716. Soodini G, Morgan J P. Can cocaine abuse exacerbate the cardiac toxicity of human immunodeficiency virus? Clinical Cardiology. 2001;24(3):177–181. [PubMed: 11288961]
  717. Spencer S S. Tuberculosis: Facing new threats from an old enemy. Corrections Today 54(7):98. 1992;100:102–103.
  718. Spiegel D A. Psychological strategies for discontinuing benzodiazepine treatment. Journal of Clinical Psychopharmacology. 1999;19(6 Suppl 2):17S–22S. [PubMed: 10587280]
  719. Spray, J.R., and Jones, S.M. The Use of Acupuncture in Drug Addiction Treatment. News Briefs. Washington, DC: National Drug Strategy Network, 1995. http://www.ndsn.org/SEPT95/GUEST.html[Accessed September 4, 2001].
  720. Stark M J, Campbell B K, Brinkerhoff C V. “Hello, may we help you?” A study of attrition prevention at the time of the first phone contact with substance-abusing clients. American Journal of Drug and Alcohol Abuse. 1990;16(1 and 2):67–76. [PubMed: 2330937]
  721. Stedman, T.L. Stedman's Medical Dictionary. 25th ed. Baltimore: Williams & Wilkins, 1990.
  722. Steenrod S, Brisson A, McCarty D, Hodgkin D. Effects of managed care on programs and practices for the treatment of alcohol and drug dependence. Recent Developments in Alcoholism. 2001;15:51–71. [PubMed: 11449757]
  723. Stein B, Orlando M, Sturm R. The effect of copayments on drug and alcohol treatment following inpatient detoxification under managed care. Psychiatric Services. 2000;51(2):195–198. [PubMed: 10655002]
  724. Stein, J.H., ed. Internal Medicine. 4th ed. St. Louis, MO: Mosby-Year Book, Inc., 1994.
  725. Stevens S J, Estrada A L, Glider P J, McGrath R A. Ethnic and cultural differences in drug-using women who are in and out of treatment. Drugs and Society. 1997;13(1–2):81–95.
  726. Stine, S.M., Greenwald, M.K., and Kosten, T.R. Ultra Rapid Opiate Detoxification. In: Graham, A.W., Schultz, T.K., Mayo-Smith, M.F., Ries, R.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 3d ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003. pp. 668–669.
  727. Stitzer, M.L., and Higgins, S.T. Behavioral treatment of drug and alcohol abuse. In: Bloom, F.E., and Kupfer, D., eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995. pp. 1807–1819.
  728. Strakowski S M, DelBello M P. The co-occurrence of bipolar and substance use disorders. Clinical Psychology Review. 2000;20(2):191–206. [PubMed: 10721497]
  729. Strobbe S, Brower K J, Galen L W. Predicting completion of outpatient opioid detoxification with clonidine. American Journal on Addictions. 2003;12(3):260–269. [PubMed: 12851022]
  730. Stuyt E B. Recovery rates after treatment for alcohol/drug dependence: Tobacco users vs. non-tobacco users. American Journal on Addictions. 1997;6(2):159–167. [PubMed: 9134078]
  731. Substance Abuse and Mental Health Services Administration. The Drug Addiction Treatment Act of 2000 (DATA 2000). Rockville, MD: Substance Abuse and Mental Health Services Administration, 2002. http://buprenorphine.samhsa.gov/data.html[Accessed October 31, 2002].
  732. Substance Abuse and Mental Health Services Administration. Summary Report—A National Call to Action: Eliminating the Use of Seclusion and Restraint. SAMHSA Matrix: Seclusion and Restraint. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2003. http://alt.samhsa.gov/seclusion/SRMay5report2.htm[Accessed January 20, 2006].
  733. Sue D. Multicultural training. International Journal of Intercultural Relations. 1997;21(2):175–193.
  734. Sue, D.W., and Sue, D. Counseling the Culturally Different: Theory and Practice. 3d ed. New York: John Wiley and Sons, 1999.
  735. Sue S. Community mental health services to minority groups: Some optimism, some pessimism. American Psychologist. 1977;32(8):616–624. [PubMed: 889163]
  736. Sullivan J T, Sykora K, Schneiderman J, Naranjo C A, Sellers E M. Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction. 1989;84(11):1353–1357. [PubMed: 2597811]
  737. Sullivan M L, Martinez C M, Gallagher E J. Atrial fibrillation and anabolic steroids. Journal of Emergency Medicine. 1999;17(5):851–857. [PubMed: 10499702]
  738. Summers J, Zisook S, Atkinson J H, Sciolla A, Whitehall W, Brown S, Patterson T, Grant I. Psychiatric morbidity associated with acquired immune deficiency syndrome-related grief resolution. Journal of Nervous and Mental Disease. 1995;183(6):384–389. [PubMed: 7798087]
  739. Sutocky J W, Shultz J M, Kizer K W. Alcohol-related mortality in California, 1980 to 1989. American Journal of Public Health. 1993;83(6):817–823. [PMC free article: PMC1694745] [PubMed: 8498618]
  740. Sutton L R, Hinderliter S A. Diazepam abuse in pregnant women on methadone maintenance. Implications for the neonate. Clinical Pediatrics. 1990;29(2):108–111. [PubMed: 2302898]
  741. Svikis D S, Golden A S, Huggins G R, Pickens R W. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug and Alcohol Dependence. 1997;45(1–2):105–113. [PubMed: 9179512]
  742. Swift R M, Miller N S. Integration of health care economics for addiction treatment in clinic care. Journal of Psychoactive Drugs. 1997;29(3):255–262. [PubMed: 9339857]
  743. Tamerin J S, Mendelson J H. The psychodynamics of chronic inebriation: Observations of alcoholics during the process of drinking in an experimental group setting. American Journal of Psychiatry. 1969;125(7):886–899. [PubMed: 5765626]
  744. Tang, W.W.H., and Bigby, J. Cultural perspectives on substance abuse. In: Friedman, L., Fleming, N., Roberts, D., and Hyman, S.E., eds. Source Book of Substance Abuse and Addiction. Baltimore: Williams & Wilkins, 1996. pp. 41–36.
  745. Tarasoff v. Regents of Univ of CA. 17 Cal.3d 425 (1976), 1976.
  746. Thase M E, Salloum I M, Cornelius J D. Comorbid alcoholism and depression: Treatment issues. Journal of Clinical Psychiatry. 2001;62(Suppl 20):32–41. [PubMed: 11584873]
  747. Thomas-Knight, R. Treating Alcoholism Among the Aged: The Effectiveness of a Special Treatment Program for Older Problem Drinkers. Fayetteville, AR: University of Arkansas, 1978.
  748. Thompson M P, Kingree J B. The frequency and impact of violent trauma among pregnant substance abusers. Addictive Behaviors. 1998;23(2):257–262. [PubMed: 9573429]
  749. Thornton C C, Gottheil E, Weinstein S P, Kerachsky R S. Patient-treatment matching in substance abuse: Drug addiction severity. Journal of Substance Abuse Treatment. 1998;15(6):505–511. [PubMed: 9845864]
  750. Thurman, P.J., Swaim, R.C., and Plested, B. Intervention and treatment of ethnic minority substance abusers. In: Aponte, J.F., and Rivers, R.Y., eds. Psychological Interventions and Cultural Diversity. Boston: Allyn and Bacon, 1995. pp. 215–233.
  751. Tonigan J S, Toscova R, Miller W R. Meta-analysis of the literature on Alcoholics Anonymous: Sample and study characteristics moderate findings. Journal of Studies on Alcohol. 1996;57(1):65–72. [PubMed: 8747503]
  752. Tonnesen H, Kehlet H. Preoperative alcoholism and postoperative morbidity. British Journal of Surgery. 1999;86(7):869–874. [PubMed: 10417555]
  753. Trachtenberg, A.I. Testimony to the White House Commission on Complementary and Alternative Medicine Policy, December 18, 2000. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2000. http://www.samhsa.gov/centers/csat/content/dpt/010223testimony.htm[Accessed March 31, 2003].
  754. Trevillyan J, Carroll P J. Management of portal hypertension and esophageal varices in alcoholic cirrhosis. American Family Physician. 1997;55(5):1851–1858. [PubMed: 9105210]
  755. Trudeau D L, Isenhart C, Silversmith D. Efficacy of smoking cessation strategies in a treatment program. Journal of Addictive Diseases. 1995;14(1):109–116. [PubMed: 7632744]
  756. Tsai G E, Ragan P, Change R, Chen S, Linnoila M I, Coyle J T. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. American Journal of Psychiatry. 1998;155(6):726–732. [PubMed: 9619143]
  757. U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication No. (CDC) 90-8416. Rockville, MD: U.S. Department of Health and Human Services, Centers for Disease Control, Office on Smoking and Health, 1990.
  758. U.S. Department of Health and Human Services. Tobacco Use Among U.S. Racial/Ethnic Minority Groups-African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1998. http://www.cdc.gov/tobacco/sgr-minorities.htm[Accessed April 25, 2003].
  759. U.S. Department of Health and Human Services. Mental Health: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999. http://www.surgeongeneral.gov/library/mentalhealth/home.html[Accessed March 18, 2002].
  760. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. Washington, DC: U.S. Government Printing Office, 2000a. http://www.health.gov/healthypeople/Document/pdf/uih/2010uandih.pdf[Accessed April 17, 2002].
  761. U.S. Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000b. http://www.cdc.gov/tobacco/sgr_tobacco_use.htm[Accessed July 17, 2001].
  762. U.S. Department of Health and Human Services. Mental Health: Culture, Race, and Ethnicity. A Supplement to Mental Health: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, 2001.
  763. U.S. Department of Health and Human Services. Regional Differences in Indian Health 1998-99. Rockville, MD: Indian Health Service, 2002a. http://www.ihs.gov/PublicInfo/Publications/trends98/master.pdf[Accessed July 23, 2002].
  764. U.S. Department of Health and Human Services. Substance Abuse--A National Challenge Prevention, Treatment and Research at HHS. Washington, DC: U.S. Department of Health and Human Services, 2-27-2002b. http://www.hhs.gov/news/press/2002pres/subabuse.html[Accessed May 22, 2002].
  765. U.S. Department of Health and Human Services. Substance Abuse—A National Challenge: Prevention, Treatment and Research at HHS. Fact Sheet. Washington, DC: U.S. Department of Health and Human Services, 2003. http://www.hhs.gov/news/press/2002pres/subabuse.html[Accessed January 5, 2005].
  766. Van Hoozen B E, Cross C E. Marijuana. Respiratory tract effects. Clinical Reviews in Allergy and Immunology. 1997;15(3):243–269. [PubMed: 9358987]
  767. Vega W A, Kolody B, Aguilar-Gaxiola S, Alderete E, Catalano R, Caraveo-Anduaga J. Lifetime prevalence of DSM-III-R psychiatric disorders among urban and rural Mexican Americans in California. Archives of General Psychiatry. 1998;55(9):771–778. [PubMed: 9736002]
  768. Victor M, Adams R D. The effects of alcohol on the nervous system. Proceedings of the Association for Research in Nervous and Mental Disease. 1953;32:525–573.
  769. Vining E, Kosten T R, Kleber H D. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. British Journal of Addiction. 1988;83(5):567–575. [PubMed: 3382815]
  770. Voas R B, Fisher D A. Court procedures for handling intoxicated drivers. Alcohol Research and Health. 2002;25(1):32–42. [PubMed: 11496964]
  771. Volk R J, Steinbauer J R, Cantor S B, Holzer C E III. The Alcohol Use Disorders Identification Test (AUDIT) as a screen for at-risk drinking in primary care patients of different racial/ethnic backgrounds. Addiction. 1997;92(2):197–206. [PubMed: 9158231]
  772. Waksman J, Taylor R N, Bodor G S, Daly F F, Jolliff H A, Dart R C. Acute myocardial infarction associated with amphetamine use. Mayo Clinic Proceedings. 2001;76(3):323–326. [PubMed: 11243281]
  773. Walsh D C, Hingson R W, Merrigan D M, Levenson S M, Cupples L A, Heeren T, Coffman G A, Becker C A, Barker T A, Hamilton S K. A randomized trial of treatment options for alcohol-abusing workers. New England Journal of Medicine. 1991;325(11):775–782. [PubMed: 1870651]
  774. Walsh S L, Preston K L, Stitzer M L, Cone E J, Bigelow G E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics. 1994;55(5):569–580. [PubMed: 8181201]
  775. Wartenberg A A, Nirenberg T D, Liepman M R, Silvia L Y, Begin A M, Monti P M. Detoxification of alcoholics: Improving care by symptom-triggered sedation. Alcoholism: Clinical and Experimental Research. 1990;14(1):71–75.
  776. Washburn A M, Fullilove R E, Fullilove M T, Keenan P A, McGee B, Morris K A, Sorensen J L, Clark W W. Acupuncture heroin detoxification: A single-blind clinical trial. Journal of Substance Abuse Treatment. 1993;10(4):345–351. [PubMed: 8411294]
  777. Weddington W W, Brown B S, Haertzen C A, Cone E J, Dax E M, Herning R I, Michaelson B S. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts: A controlled residential study. Archives of General Psychiatry. 1990;47(September):861–868. [PubMed: 2393345]
  778. Weisner C, Mertens J, Tam T, Moore C. Factors affecting the initiation of substance abuse treatment in managed care. Addiction. 2001;96(5):705–716. [PubMed: 11331029]
  779. Wesson, D.R., and Smith, D.E. Cocaine: Treatment perspectives. In: Kozel, N.J., and Adams, E.H., eds. Cocaine Use in America: Epidemiologic and Clinical Perspectives. NIDA Research Monograph No. 61. DHHS Publication No. ADM 85-1414. Rockville, MD: National Institute on Drug Abuse, 1985. pp. 193–203.
  780. West P M, Graham K. Clients speak: Participatory evaluation of a nonconfrontational addictions treatment program for older adults. Journal of Aging and Health. 1999;11(4):540–564. [PubMed: 10848077]
  781. Westermeyer, J. Substance-related disorders. In: Ammerman, R.T., and Hersen, M., eds. Handbook of Prevention and Treatment With Children and Adolescents: Intervention in the Real World Context. New York: John Wiley and Sons, 1997. pp. 604–628.
  782. Westermeyer J, Neider J. Predicting treatment outcome after ten years among American Indian alcoholics. Alcoholism: Clinical and Experimental Research. 1984;8(2):179–184.
  783. Westermeyer J, Specker S, Neider J, Lingenfelter M A. Substance abuse and associated psychiatric disorder among 100 adolescents. Journal of Addictive Diseases. 1994;13(1):67–89. [PubMed: 8018741]
  784. Western Interstate Commission for Higher Education. Cultural Competence Standards in Managed Mental Health Care for Four Underserved/Underrepresented Racial/Ethnic Groups. Boulder, CO: Western Interstate Commission for Higher Education, 2000. http://www.wiche.edu/MentalHealth/Cultural_Comp/ccslist.htm[Accessed January 18, 2005].
  785. Westmaas J L, Nath V, Brandon T H. Contemporary smoking cessation. Cancer Control. 2000;7(1):56–62. [PubMed: 10740661]
  786. Westman E C, Tomlin K F, Rose J E. Combining the nicotine inhaler and nicotine patch for smoking cessation. American Journal of Health Behavior. 2000;24(2):114–119.
  787. Wetterling T, Rolf-Dieter K, Bester B. A new rating scale for the assessment of the alcohol withdrawal syndrome (AWS) scale. Alcohol and Alcoholism. 1997;32(6):753–760. [PubMed: 9463730]
  788. Wetterling T, Veltrup C, Driessen M, John U. Drinking pattern and alcohol-related medical disorders. Alcohol and Alcoholism. 1999;34(3):330–336. [PubMed: 10414607]
  789. Whitfield C L, Thompson G, Lamb A, Spencer V, Pfeifer M, Browning-Ferrando M. Detoxification of 1,024 alcoholic patients without psychoactive drugs. Journal of the American Medical Association. 1978;239(14):1409–1410. [PubMed: 633543]
  790. Whittington R A, Collins E D, Kleber H D. Rapid opioid detoxification during general anesthesia: Is death not a significant outcome? Anesthesiology. 2000;93(5):1363–1364. [PubMed: 11046233]
  791. Wiesbeck G A, Schuckit M A, Kalmijn J A, Tipp J E, Bucholz K K, Smith T L. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction. 1996;91(10):1469–1478. [PubMed: 8917915]
  792. Wilbur R, Kulik F A. Anticonvulsant drugs in alcohol withdrawal: Use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants. American Journal of Hospital Pharmacy. 1981;38(8):1138–1143. [PubMed: 6791497]
  793. Wilkins, J.N., Conner, B.T., and Gorelick, D.A. Management of stimulant, hallucinogen, marijuana and phencyclidine intoxication and withdrawal. In: Graham, A.W., Schultz, T.K., and Wilford, B.B., eds. Principles of Addiction Medicine. 2d ed. Chevy Chase, MD: American Society of Addiction Medicine, 1998. pp. 465–485.
  794. Wojnar M, Bizon Z, Wasilewski D. Assessment of the role of kindling in the pathogenesis of alcohol withdrawal seizures and delirium tremens. Alcoholism: Clinical and Experimental Research. 1999;23(2):204–208.
  795. Wolff P H. Ethnic differences in alcohol sensitivity. Science. 1972;175(20):449–450. [PubMed: 5007912]
  796. Wolff P H. Vasomotor sensitivity to alcohol in diverse Mongoloid populations. American Journal of Human Genetics. 1973;25(2):193–199. [PMC free article: PMC1762515] [PubMed: 4689039]
  797. World Health Organization. International Classification of Impairments, Disabilities, and Handicaps: A Manual of Classification Relating to the Consequences of Disease. Geneva: World Health Organization, 1980.
  798. Worner T M. Relative kindling effect of readmissions in alcoholics. Alcohol and Alcoholism. 1996;31(4):375–380. [PubMed: 8879284]
  799. Yakshe, P. Pancreatitis, Chronic. eMedicine. Omaha, NE: eMedicine.com, 2004. http://www.emedicine.com/MED/topic1721.htm[Accessed January 21, 2005].
  800. Yates, B.T. Analyzing Costs, Procedures, Processes, and Outcomes in Human Services. Applied Social Research Methods Series V. 42. Thousand Oaks, CA: Sage, 1996.
  801. Yates, B.T. Measuring and Improving Cost, Cost-Effectiveness, and Cost-Benefit for Substance Abuse Treatment Programs: A Manual. NIH Publication Number 99-4518. Rockville, MD: National Institute on Drug Abuse, 1999. http://www.nida.nih.gov/PDF/Costs.pdf[Accessed February 25, 2005].
  802. Yen S, Robins C J, Lin N. A cross-cultural comparison of depressive symptom manifestation: China and the United States. Journal of Consulting and Clinical Psychology. 2000;68(6):993–999. [PubMed: 11142551]
  803. Yesalis C E, Kennedy N J, Kopstein A N, Bahrke M S. Anabolic-androgenic steroid use in the United States. Journal of the American Medical Association. 1993;270(10):1217–1221. [PubMed: 8355384]
  804. Yeung A, Neault N, Sonawalla S, Howarth S, Fava M, Nierenberg A A. Screening for major depression in Asian-Americans: A comparison of the Beck and the Chinese Depression Inventory. Acta Psychiatrica Scandinavica. 2002;105(4):252–257. [PubMed: 11942928]
  805. Yoshida A, Ikawa M, Hsu L C, Tani K. Molecular abnormality and DNA cloning of human aldehyde dehydrogenases. Alcohol. 1985;2(1):103–106. [PubMed: 4015823]
  806. Yoshihara H, Noda K, Kamada T. Interrelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma. Recent Developments in Alcoholism. 1998;14:457–469. [PubMed: 9751959]
  807. Yoshikawa T, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawasaki S, Yanagida M. Effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding: Use of fluorescent probes. Clinical Pharmacology and Therapeutics. 1984;36(2):201–208. [PubMed: 6744779]
  808. Zador D, Lyons Wall P M, Webster I. High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. Addiction. 1996;91(7):1053–1061. [PubMed: 8688819]
  809. Zakhari S. Vulnerability to cardiac disease. Recent Developments in Alcoholism. 1991;9:225–260. [PubMed: 1758986]
  810. Zarkin G A, Dunlap L J, Homsi G. The substance abuse services cost analysis program (SASCAP): A new method for estimating drug treatment services costs. Evaluation and Program Planning. 2004;27(1):35–43.
  811. Zevin S, Benowitz N L. Drug interactions with tobacco smoking. An update. Clinical Pharmacokinetics. 1999;36(6):425–438. [PubMed: 10427467]
  812. Zhang A Y, Snowden L R. Ethnic characteristics of mental disorders in five U.S. communities. Cultural Diversity and Ethnic Minority Psychology. 1999;5:134–146. [PubMed: 15605683]
  813. Zimberg S. Two types of problem drinkers: Both can be managed. Geriatrics. 1974;29(8):135–139. [PubMed: 4843040]

Copyright Notice: http://www.ncbi.nlm.nih.gov/books/about/copyright/

Print View 
Cover of Detoxification and Substance Abuse Treatment
Detoxification and Substance Abuse Treatment.
Show details
Order print copy from SAMHSA

Download

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > Bookshelf
Write to the Help Desk